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Abstract
The literature on neuropsychological functioning in patients with asymptomatic
HIV disease is widely discrepant with prominent researchers on either side o f the
debate about whether or not early HIV infection is associated with neuropsychological
deficits. Many theories have been put forth to account for these varied results,
including inadequate study design, lack of measures sensitive enough to detect
differences, and pooling of test scores across individuals that do have deficits, but not
necessarily in the same areas.
The present investigation was designed to examine the role o f anxiety as a
possible confounding variable that could account for differences across HIV serostatus
groups. It also investigated the hypothesis that HIV seropositive and HIV seronegative
patients differ in terms o f their appraisals of their performance and that higher levels of
anxiety are related to lowered estimation of performance.
The HIV seropositive and HIV seronegative groups in this investigation did not
differ in terms of their neurocognitive functioning. When the groups were further
divided in terms of their anxiety level, again there were no differences in their
neurocognitive functioning. The investigation therefore failed to identify anxiety as a
contributor to neuropsychological dysfunction in HTV seropositive subjects, however,
given the lack of HIV group differences in neurocognitive functioning, it did not rule
out a potential role for anxiety either.
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Further, there was no difference between the groups divided based on HTV
serostatus and anxiety level in terms of their ability to accurately appraise their
performance. All participants were able to estimate their performances very accurately.
Finally, medication effects were investigated. There were no differences in
performance on neuropsychological tests found between the HIV seropositive subjects
who followed a medication regimen and those who did not.
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Introduction
The latest statistics released by the Centers for Disease Control and Prevention
(1996) show that through December 31, 1996, 581,429 people in the United States had
been diagnosed with AIDS. Many more persons are living with HIV, but estimates of
the number are conservatively skewed because many states do not require health
department notification of positive tests for HTV, and many people with HIV have not
yet been tested. The largest percentage of AIDS patients remained men who have sex
with other men (homosexuals and bisexuals) at 50%, although this percentage has
declined since monitoring of the disease began. These numbers demonstrate that
although the first cases of HTV transmission were reported in homosexual men, the
trend in cases of newly reported HTV infections is away from the homosexual
population, and toward IV drug users and their partners. In fact, among women,
heterosexual contact and intravenous drug use accounted for 40 and 34 percent,
respectively. Of all AIDS cases, 573,800 were adults and adolescents, and 7,629 fell
into the category of pediatric AIDS (under 13 years of age). Caucasians accounted for
46.2% of all AIDS cases, 34.9% were African-American, 19.0% were Hispanic, 0.8%
were Asians or Pacific Islanders, and 0.3% were American Indians or Native Alaskans.
Heyward and Curran (1989) note that the disproportionately large number of cases in
African- and Hispanic-Americans can be attributed to intravenous (IV) drug use and
sexual relations with partners who are IV drug users, and the percentage of African- and
Hispanic-Americans among AIDS cases continues to climb at a faster rate than among
any other group.
1
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Through mid-1995 AIDS was listed as the cause o f death for 357,598 people in
the United States and many more people worldwide, but research continues into ways
to halt the spread of the disease, and according to the CDC the death rate from AIDS in
1996 was down 19% from the previous year, probably due to advances in medical care
of HIV-seropositive patients (“AIDS Deaths are Down,” 1997). The causative agent of
AIDS has been established as the Human Immunodeficiency Virus, or HIV, and the
means of infection by the virus have been well delineated. The virus is passed from one
host to another in the bodily fluids - through shared blood, sexual intercourse, and from
mother to child, in utero or through breast feeding (Gallo & Montagnier, 1989).
According to Gallo and Montagnier (1989), until a cure can be found, the greatest
chance of curbing the epidemic is through knowledge about HTV and its modes of
transmission with the expectation that this knowledge will lead to behavioral changes
away from risky behavior. A look back at the discovery of HIV is appropriate at this
point in order to chart the progress that has been made in the study of this disease.
History of HIV
According to all published reports, the first cases of AIDS in the United States
were in young homosexual men, and it soon became apparent from their symptoms that
they had suffered a loss of T-cells (immune system cells). As in the diseases caused by
Human T-cell Lymphotropic Viruses - 1and - n, two retroviruses, the immune system
was compromised, and like these two viruses, the AIDS pathogen had been shown to be
transmitted through blood and sexual intercourse. Because o f these commonalities,
Gallo and his colleagues (1984) proposed that the agent responsible for AIDS was a
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retrovirus related to HTLV-I and -II (Gallo & Montagnier, 1989). Retroviruses differ
from other viruses in that their genetic material is RNA rather than DNA. Whereas in
all other cells, the flow of genetic information is from DNA to RNA to proteins, the
flow is reversed in retroviruses. Information coded in viral RNA is converted into DNA
which is then incorporated into the host cell DNA where it is transcribed to messenger
RNA, and its proteins are constructed. The retroviruses are able to accomplish this
reverse transcription with the help of the enzyme reverse transcriptase.
Early in the history of the study of HIV, several teams of researchers claimed its
discovery, variously labeling it, HTLV-HI, LAV (Lymphadenopathy-associated virus),
and ARV (AIDS associated retrovirus) (Knapp & VandeCreek, 1990). With the
development o f more sophisticated techniques for investigation, it was determined that
all three were the same virus and the name was changed to HIV. HIV is now often
referred to as HTV-1 to distinguish it from a structural variant HIV-2 which produces
similar clinical symptoms but is primarily seen in Africa (Knapp & VandeCreek, 1990).
Because the virus variant most commonly seen within this country is HIV-1, HIV in this
paper will refer to HTV-1.
Once HIV was isolated, the next step in the process involved determining its life
cycle and the means by which it causes AIDS.
Pathophysiology o f HIV
HIV is a retrovirus, and as most viruses, it cannot replicate on its own. It
therefore needs the DNA of a host cell to carry out its replication in order to produce
more viruses. Unlike most viruses, however, because HIV is a retrovirus, it's genetic
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material is a single strand of RNA rather than DNA. Therefore, in order to insert its
own genetic material into the host cell's DNA an intermediate step must take place, for
this conversion of viral RNA to DNA, the virus uses reverse transcriptase.
HIV primarily attacks and destroys T4 immune cells (helper T-lymphocytes)
which are at the front lines o f the immune system attack on foreign invaders. T4-cells
are also often referred to as CD4 cells because of the CD4 receptor on the cell's surface.
According to McDougal, Mawle, and Nicholson (1989), it is most helpful to view the
infection with HTV in three stages; infection, replication, and consequences for the
infected cell. The infection phase begins with binding of the virus to the host cell. The
CD4 receptor has an affinity for a protein on the coat o f the virus, gpl20, and binds
tightly to it. Next, the virus merges with the T-cell and uses reverse transcriptase, to
transcribe the HIV's RNA into DNA. The DNA is then incorporated into the host cell's
genetic structure and there it directs the production o f new viral RNA and proteins. The
proteins then combine to form new virus particles (replication phase) (Redfield &
Burke, 1989). The new viruses then bud from the T-cell membrane and infect other
cells. The death o f the cell is the ultimate consequence o f the infection, but the virus
may, for a time, simply impair the functioning of the cell, or the two could live
symbiotically until the virus finally kills the cell (McDougal, Mawle, & Nicholson,
1989).
Originally, it was discovered that HIV could kill the helper T-cells by
multiplying to great numbers inside them and in that way kill them. This finding led
many early researchers to propose that viral replication alone was responsible for the
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cell death associated with infection. Since that time, it has been shown that only a small
fraction o f T-cells display the viral replication necessary for the virus to destroy the
host cells, and this number is not sufficient to account for the extreme
immunosuppression in AIDS patients. The only way for later researchers to account for
the large number of cells killed was to postulate other methods of cell destruction.
Several mechanisms have been proposed and demonstrated in vitro, however it is not
yet known if these mechanisms actually occur in the body (Redfield & Burke, 1989).
Sodroski, et al. (1986) and Redfield and Burke (1989) have described the
formation of syncytia as a possible means to explain the mass destruction of T-cells. In
this formulation, the infected T-cells fuse with uninfected T-cells and form massive
multinucleated cells that can no longer function properly, and as a result die.
Redfield and Burke (1989) also propose that the infected T-cells that are not producing
new viral particles may be sought out and killed by the body's natural immune activity.
Similarly, they describe a way that even uninfected T-cells might be destroyed by the
patient's own body. In a process that is unique to HIV the gp 120 proteins that are
normally part of the virus can break off and circulate freely in the body. Because the Tcell receptor has such a strong affinity for this protein, it attaches to the free floating
gpl20. When the immune system recognizes the gp 120 as a foreign agent, it destroys
the protein and the cell to which it is attached. In this way, healthy T-cells can be
destroyed by the immune system o f which they are a part
Additionally, the CD4 receptor is not limited to the T- cells. It is also found on
various other cells in the immune system. Hence, the virus can bind to and replicate in
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monocytes, macrophages, and similar cells called tissue-dendritic cells found in the
skin, mucous membranes, lymph nodes, liver, spleen, and brain (Redfield & Burke,
1989). Apparently these cells are not destroyed by the HIV, but their functioning is
disturbed leading to further systemic immunosuppression.
Further complicating this scenario is the fact that it was discovered that the rate
of cell death differs between non-activated T-cells and T-cells that have been mobilized
to fight infection (Fouchard, Desportes, Reveil, Leonard, Gallo & Zagury, 1986;
McDougal, et al., 1985; Redfield & Burke, 1989, Zagury, et al., 1986). Therefore not
only are patients more susceptible to infectious agents, but when T-cells are activated to
combat these infections, the activation leads to increased replication of the virus and
death of the T-cells. Further, when the T-cells are activated to combat the newly
invading HTV, this stimulates replication of the virus in the same way that another
infection would, leading to the paradox that the body's very means of fighting the
disease aids in its proliferation. Regardless of the mechanism o f cell death it remains a
fact that the T-cell count of the HTV infected patient declines throughout his/her life
and eventually the immune system is so thoroughly compromised that it can no longer
function.
Physiological Aspects o f HIV Disease
According to Rogers and Masur (1989), seroconversion to HTV positive status
usually occurs between 8 and 12 weeks afier the presumed exposure. Upon
seroconversion, some patients experience a mononucleosis-like syndrome (Cooper, et
al., 1985; Redfield & Burke, 1989). The initial symptoms include fever, fatigue,
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swollen glands, sweats, muscle aches, headache, sore throats and often rashes. With
treatments, however, these symptoms disappear and the patient returns to a healthy
state. Unfortunately the symptoms disappear, but the virus continues to live in the host.
The patient can remain in this state for several years, but the next stage of the disease
will ensue if the patient does not die of other causes. The patient's lymph nodes also
become chronically enlarged (Redfield & Burke, 1989). According to Redfield and
Burke (1989) the presence o f the overabundance o f HTV in the lymph nodes
overstimulates B-cells (another type of immune cell) and keeps them in a chronic state
of activation, thus causing the lymphadenopathy. Others (Brandon, 1993) have
suggested that the virus may be "hiding out" in the lymph nodes and replicating at a
high rate, thus accounting for the lymphadenopathy as well as for the latency period
after original seroconversion but before symptoms of ADDS appear.
The T-cell count then begins a steady decline and the immune system becomes
further compromised. Infectious agents enter the body more easily, and they are harder
to fight. At this point with the T-cell count begins dropping rapidly, opportunistic
infections, (from normally benign pathogens that may now take advantage of a
weakened immune system) begin to appear.
The most recent revision of the CDC classification system for HIV disease
(CDC, 1992) greatly increased the number o f AIDS cases being reported over previous
systems because it takes into account the number o f T-cells remaining in a patient that
has been diagnosed as HTV positive as well as the number of additional infections that
the patient suffers. A discussion o f this system is pertinent at this time because it helps
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to illuminate the progression o f the disease state. The system consists o f three
categories involving the number of T-lymphocytes the person has, and three clinical
categories. The three T cell categories are:
Category 1: > or = 500 cell/microliter of blood
Category 2: 200 - 499 cells/microliter of blood
Category 3: < 200 cell/microliter o f blood
The three clinical categories include:
Category A: no condition listed in category B or C and one or more of the
conditions listed in Appendix A.
Category B: Symptomatic conditions present that are not included in category C,
and the conditions either are attributed to compromised immune functioning, or are of a
nature to have a clinical course or require management that is complicated by HIV.
Examples of conditions in category B can be but are not limited to those conditions
listed in Appendix B.
Category B conditions take precedent over Category A and once a patient has
entered Category B, he or she cannot be returned to Category A.
Category C: Includes all clinical conditions listed in the AIDS surveillance case
definition (Appendix C). Additionally, Category C conditions take precedence over all
others, and once a patient has entered Category C he or she will remain in that category.
(See Table 1).
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Table 1
1993 Revised Classification System for HIV Infection and Expanded AIDS
Surveillance Case Definition for Adolescents and Adults.
Clinical Categories
T cell
Categories

A
Asymptomatic

1: > or = 500

Al

B
Symptomatic, not
A or C conditions
B1

2:200-499

A2

B2

C
AIDS-indicator
conditions

cr

C2*

B3*
C3*
3: < 200 (AIDS-indicator
A3*
T cell count)
*= Indicates reportable AIDS cases either based on the number of T-cells per microliter
of blood, or based on the presence of clinical conditions listed in the AIDS surveillance
case definition (Appendix A).

Neuropsychological Manifestations of HIV
Early in the history of AIDS research, several groups had already begun to note
neurological deficits that were affecting the long-term survivors of HIV disease
(Gopinathan, Laubenstein, Mondale, Krigel, 1983; Herman, 1983; Kermani, Drob, &
Alpert, 1984). Initially, it was thought to be the result of a subacute encephalopathy due
to cytomegalovirus, but the finding that HTV could enter the brain led to the theory that
HIV invades the brain, and disrupts neuropsychological functioning in those who have
survived the longest (Navia, 1990). In 1986, Navia and his colleagues (Navia, Jordan, &
Price, 1986b) became the first to define what they termed "AIDS Dementia Complex
(ADC)." The term AIDS, rather than HTV, was used because at that time, it was not
widely known that HTV was the pathogen that caused the immune disorder. The
patients that they described were inpatients who demonstrated disturbance of motor
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performance, behavior, and global cognitive impairment. Hence the term AIDS
Dementia Complex was coined.
According to Perry (1990), the term is a misnomer because patients have been
shown to have mental changes without the systemic manifestations of AIDS. Also,
these early disturbances may not predominantly involve higher cortical functioning (as
in dementia), and the complex of cognitive, motor, and behavioral impairment may not
always be present.
In response to criticisms such as Perry's, the American Academy of Neurology
AIDS Task Force (1991) has proposed a standard nomenclature for the neurologic
manifestations of HIV-1 infection. The task force has separated the complex into two
categories. The more severe form, HTV-1 - associated dementia complex or HTV-1 associated myelopathy, includes the complex of disturbed motor performance,
behavioral changes, and global cognitive impairment sufficient to disrupt social or
occupational functioning. A less severe form, HIV-1 associated minor cognitive/motor
disorder, describes the situation in which not all of these deficits are present, or in
which the disturbance is not great enough to cause impairment in social or occupational
functioning. By the current CDC classification system, the manifestations of the severe
form are sufficient for a diagnosis of AIDS, while the manifestations of the less severe
form are not, although they may be present in persons with AIDS. The task force further
states that it is not known at this time if the two forms are the same entity, or even if the
minor form will inevitably progress to the severe form. Despite the recommendations of
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the task force, however, the term AIDS Dementia Complex has continued to be used in
the literature.
Soon after the first reports of ADC, researchers began to elucidate the exact
nature of the dysfunction. Investigations were designed to focus on the specifics of the
disorder such as timing as well as the exact structures and pathways affected by the
pathogen. It has been estimated that neuropathological abnormalities are present in
70% to 90% of the brains o f AIDS patients (Ho, Bredesen, Vinters, & Daar, 1989;
Vinters, Tomiyasu, & Anders, 1989).
Neuroanatomical Changes in HIV Disease
According to Navia (1990), the most frequent structural changes that have been
noted on CT and MRI consist o f diffuse cerebral atrophy of varying severity, sometimes
associated with ventricular dilation. He also noted that these changes have been
detected months before the onset ofovert dementia. Less frequently, either patchy or
diffuse attenuation o f the white matter may be observed on CT scans, although MRI is
more sensitive in detecting this abnormality. In an earlier paper, he noted that similar
changes have also been noted in the basal ganglia and the thalamus (Navia, Cho, Petito,
& Price, 1986a). Wcssdingh ct al. (1993), however, have noted that the structural
changes seen are relatively mild, and do not provide a satisfying explanation for the
clinical picture.
Characteristic histological changes that have been noted are most often in
subcortical structures, primarily in the central white and deep gray matter in the basal
ganglia and the thalamus, with relative sparing of the cortical structures (Navia et al.,
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1986b). Navia (1990) has reported that positron emission tomography (PET) studies
show hypermetabolism of radioactive glucose in subcortical structures early, and both
cortical and subcortical structures late. Additional findings have included focal necrosis
and vacuolation of the white matter and focal or diffuse demyelination. These changes
in brain histology can vary extensively between subjects (Navia, 1990). While HIV
likely enters the brain early in the course of the infection (Chiodi et al., 1987), it is
unclear when, after the initial insult patients begin to exhibit neurologic impairment.
Pathological examination of post mortem patients, however, has shown that the severity
of clinical dementia generally correlates with the extent of brain pathology (Navia et
al., 1986b). Navia (1990) has also suggested that regional distribution of HIV parallels
neuropathy findings, with most infected cells in white and deep gray matter structures,
namely the basal ganglia and thalamus.
Along with the CNS changes of the brain, HTV disease also causes structural
changes in the spinal cord. As in the brain, the spinal cord suffers similar inflammatory
changes, with multinucleated cells and vacuolar myelopathy. These changes have been
noted primarily at the thoracic level (Navia, 1990).
It has already been mentioned that HIV is known to enter the CNS early in the
course of infection, given that HTV is present in the CSF of individuals in the early
stages of HTV disease (McArthur et al., 1989; Sonnerborg et al., 1988). It is not known
if the virus enters by itself, or is transported by infected macrophages, as most data
suggest that it is the macrophage that is primarily infected (Navia, 1990). There is
substantial evidence that HIV-1 has a direct causal role in the pathogenesis of ADC and
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ADC is not related to secondary opportunistic infection (Ho et al., 1985; Sidtis et al.,
1993).
Productive infection in the brain and spinal cord occurs in the blood-derived
macrophages, resident microglia, and multinucleated giant cells (Epstein &
Gendelman, 1993), and Geleziunas et al. (1992) have noted that the ability of HIV-1 to
localize in the CNS is probably the consequence of macrophage tropism, rather than an
affinity for neural tissue. These findings have raised an interesting dilemma in the
scientific community, and pose a difficult question that many researchers have
attempted to answer. HIV infects relatively few cells in the CNS, yet dysfunction to be
accounted for is quite extensive. What is the exact mechanism of tissue destruction that
causes the neurologic deficits in HTV disease?
Koyanogi et al. (1987) has suggested that neurotropic variants of HIV may be
partly responsible for the clinical and pathological heterogeneity o f ADC. Guilian,
Vaca, and Noonan (1990) and Lipton (1992) have gone further in suggesting that
factors other than direct infection may play a role in the development of neural cell
dysfunction, and others have agreed.
It is generally held that productive HTV infection is restricted to the
macrophage, and cell loss is relatively absent. Because the degree o f neurologic
impairment is out of proportion to the neuropathy, many researchers today feel that
brain injury could be due to secondary metabolic processes that result from the HTV
infection (Hall et al., 1991; McArthur, 1994; Navia, 1990).
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Prevailing theories have included destruction of HIV infected neural tissue, and
other variations o f the theory of immune modulated cell destruction. Navia (1990) has
suggested that neuronal dysfunction could be the result o f macrophage destruction of
latently infected neural cells, or the release of substances that are toxic to surrounding
tissues. The majority of researchers have followed the latter course in their
investigations. Immune system markers such as (32 microglobin (Elovaara et al., 1989),
quinolinic acid (Heyes et al., 1991), tumor necrosis factor a, and interleukin-6 (Tyor et
al., 1992) have all been implicated. All of these markers of immune functioning have
been found in the CSF of HTV seropositive patients. Wiley et al. (1992) have claimed
that CSF findings correlate well with one another, but not with the extent of HIV in the
brain, but Heyes et al (1991) have reported that when opportunistic infections are
controlled for, levels of quinolinic acid (a macrophage product o f tryptophan
metabolism) parallel neurologic dysfunction. Further, the cytokines IL1, and TNFa
have been shown to damage neural cells in in vitro cultures (Guilian & Lachman, 1985;
Selmaj & Raines, 1988). Additionally, (32 microglobins and quinolinic acid levels in the
CSF fall with Zidovudine (AZT; an antiretroviral medication) therapy (Brew et al.,
1989; Heyes et al., 1991). AZT at least temporarily disrupts HIV replication, and given
that AZT has been shown to ameliorate ADC (Portegies et al., 1993; Portegies et al.,
1989; Schmitt et al., 1988; Sidtis et al., 1993), this is an important finding suggesting
that HIV replication in the brain, and therefore production o f the immune modulators
plays an extensive role in neurological dysfunction.
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Another theory of neuronal destruction in HTV disease comes from Epstein and
Gendelman (1993). They suggest that HIV-1 infected macrophages can initiate
neurotoxicity, which is then amplified through cell to cell interactions with the
astrocytes. This theory has not received extensive attention in the literature.
Finally, there is clinical, imaging, and pathologic evidence that dopaminergic
neural dysfunction may be involved in the progression of ADC (Kieburtz et al., 1991).
First, a hallmark o f ADC is motor impairment Secondly, Kieburtz et al. (1991) found
that their patients were responsive to L-Dopa, although dopaminergic side effects
developed rapidly suggesting that dopamine receptors were significantly upregulated.
Finally, when dopamine blockers were given, ADC patients developed Parkinson-like
symptoms.
Specific Areas o f Dysfunction
While it has been accepted that a majority of AIDS patients will eventually
experience the neurological symptoms of HTV, the timing of the dysfunction has been
the subject of considerable debate. Several studies have reported that the decline in
functioning begins early in the disease, with early loss of cognitive functioning being
gradual and often overlooked (Navia, 1990), and greater neuropsychological
dysfunction with increasing severity of HTV disease. For example Grant et al. (1987)
reported that in their sample, nine percent of seronegative controls, forty-four percent
of asymptomatic seropositives, fifty-four percent of patients with AIDS related
complex, and eighty seven percent of AIDS patients experienced some form of
neuropsychological dysfunction. Others (Janssen et al, 1988; Perry, Belsky-Barr, Barr,
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& Jacobsberg, 1989; Wilkie, Eisdorfer, Morgan, Lowenstein, & Szapocznik, 1990)
have also argued that asymptomatic HIV positive patients are more likely than
seronegative controls to demonstrate deficits in performance.
Attention and Concentration. Although Stem, et al. (1991) have argued that
there are no deficits in the areas of attention and concentration, using the Paced
Auditory Serial Addition Test, Grant et al. (1987) has shown that there are indeed
deficits in divided attention. Further, Navia (1990) has stated that patients who have
retained insight into their illness, have complained of concentration problems stating
that tasks require much more time, and are laborious. In order to comprehend when
reading, patients must reread pages several times, and often lose their trains of thought
during conversations. Finally, he reported that patients become bewildered and
confused when presented with more than one task simultaneously.
Language. Generally, those researchers that have studied language functioning
have concluded that patients retain intact language functioning throughout their illness.
Using a confrontational naming task (the Boston Naming Test) and a word generation
test (Thurstone Word Fluency), several researchers report that symptomatic HIV
positive subjects performed as well as seronegative controls (Claypoole et al., 1990;
Goethe et al., 1989; Janssen et al., 1989; Miller et al., 1990; Olio, Johnson, & Grafman,
1991; Olio & Pass, 1988; Stem, Sano, Williams, & Gorman, 1989; Tross et al., 1988;
van Gorp, Miller, Satz, & Visscher, 1989; Wilkie et al., 1990). Contrary to these
reports, however, Perty et al. (1989) and Stem et al. (1991) report deficits in word
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generation, and Saykin et al. (1988) have found HIV seropositive patients to have
difficulty on the Boston Naming Test.
Visuospatial Functioning. As with most domains o f functioning, the results are
split in the area o f visuospatial functioning. On the Block Design subtest, Tross et al.
(1988) and van Gorp et al. (1989) have found differences between their HTV
seropositive subjects and controls. Using the Rey-Osterrieth Complex Figure Test,
however, Poutiainen, Iivanainen, Elovaara, Valle, and Lindevirta (1988) and van Gorp
et al. (1989) were unable to corroborate these results.
Verbal Memory. In the area of verbal memory functioning, Jansenn et al. (1989)
and others (Saykin et al., 1988; Wilkie et al., 1992) noted differences between HTV
seropositive and HTV seronegative subjects on the prose section of the Wechsler
Memory Scale. Likewise, several investigators have reported deficits in their HIV
seropositive subjects on the Buschke Selective Reminding Test (BSRT; Stem et al.,
1989; Stem et al., 1991; Wilkie et al., 1990). Unfortunately as in other domains of
functioning, in the area of verbal memory, a number of studies contradict the findings
of the previous researchers. Using the Rey Auditory Verbal Learning Test and the
California Verbal Learning Test, Olio and Pass (1988) and van Gorp et al. (1989) did
not find differences between HTV seropositive and HTV seronegative subjects.
Likewise, with the BSRT, Claypoole et al. (1990) and Goethe et al. (1989) failed to
note any differences.
Visual Memory. Similarly, results of testing are mixed in the area of visual
memory, with several researchers reporting deficits on the Visual Reproduction section
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of the Wechsler Memory Scale (WMS; Olio & Pass, 1988; van Gorp et al., 1989), the
Rey-Ostemeth Complex Figure Test (van Gorp et al., 1989), and the Digit Symbol
subtest of the Wechsler Adult Intelligence Scale - Revised (Janssen et al., 1989). For
every study that reports a difference in performance between HTV seropositive and HTV
seronegative subjects, it seems that another reports the opposite. For example, using the
WMS, Grant et al. (1987), Poutiainen et al. (1988), Saykin et al. (1988), and Tross et al.
(1988) did not find the differences reported by other researchers. Additionally, using
the Benton Visual Retention Test and the Tactual Performance Test, Saykin et al.
(1988) failed to find deficits among their HIV seropositive subjects.
Motor Functioning. Using tests of simple psychomotor functioning, several
researchers (Claypoole et al., 1990; Franzblau et al., 1991; Goethe et al., 1989; Olio et
al., 1991, Stem et al., 1991) were unable to find the motor deficits that are seen as a
hallmark of neuropsychological dysfunction in people with HTV associated dementia.
Others, however, reported differences between HIV seropositive and HTV seronegative
subjects (Miller et al., 1990; Saykin et al 1988; Tross et al., 1988). On tests of motor
speed, and information processing, results were equally divergent. According to van
Gorp et al. (1993), the majority of studies using the Trail Making Test part A failed to
report any deficits in functioning. By contrast, about half o f the studies using Trails B
have found differences between their HTV seropositive and HTV seronegative subjects.
Other researchers reported differences in choice reaction time, although not in simple
reaction time (Perdices & Cooper, 1989; Wilkie et al. 1990; Wilkie et al., 1992). Van
Gorp et al. (1993) attributed these deficits to cognitive slowing rather than simply to
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motoric factors. They claimed that the "slowing of psychomotor functions where
thought is wedded to action may be the cardinal feature o f HIV encephalopathy" (p.
171).
Global Cognitive Functioning. In the area of higher cortical functioning,
Claypoole et al. (1990), Grant et al. (1987), and Stem et al. (1991) all noted deficits on
tasks of abstract reasoning, whereas the findings of Rubinow, Berettini, Brouwers, and
Lane (1988) and Saykin et al. (1988) contradicted these results. Poutiainen et al. (1988),
Rubinow et al. (1988), and van Gorp et al. (1989) reported that intellectual functioning
was disturbed, and Stem et al (1989), Stem et al. (1991) and van Gorp et al (1989) all
reported low scores on the Mini Mental State Exam.
While it is generally accepted in the scientific community that people in the late
stages of HTV disease are susceptible to neurologic complications, not all researchers
agree that deficits are manifested early in the disease process. For example, several
researchers (Goethe et al., 1989; McArthur et al., 1989; Miller et al., 1990; Tross et al.,
1988) reported that their investigations revealed no differences between their
asymptomatic HIV seropositive patients and HTV seronegative controls. In 1988, the
World Health Organization (cited in van Gorp et al., 1993) stated that there is "no
evidence that otherwise healthy [HTV seropositive] individuals are more likely to be
functionally impaired than persons not infected with HTV." Seines et al. (1990) even
stated that after a follow up of one and one half years there were still no differences
between HTV seropositive and HIV seronegative subjects. However, in a recent review
of the literature, White, Heaton, Monsch, and the HTV Neurobehavioral Research
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Center Group (1995) compared the 57 studies of HTV and neuropsychological
impairment performed to the time of their review and found that according to these
investigations 35% of HTV seropositive participants evidenced some form of
neuropsychological deficit as compared to only 12% of HTV seronegative controls in
these studies.
According to van Gorp, and colleagues (1993), the general consensus among
HTV researchers is that HTV penetrates the blood-brain barrier shortly after infection,
and that some individuals will then evidence acute encephalopathic or meningitis-like
symptoms. Most people, however, show no dysfunction immediately. Although a
subsample of individuals will later develop ADC, it is not known what determines the
progression of the dysfunction. Some factors that have been suggested are (1) genetic
susceptibility of the host, (2) degree of immunosuppression, and (3) whether the variant
of HTV is neurotropic (Navia, 1990). Satz (cited in van Gorp et al., 1993) also suggested
that a determining factor of whether deficits will be found is education level. They
concluded that those studies which found no differences in cognitive functioning used
subjects with a high level of education and that the differences between asymptomatic
HIV seropositive patients and seronegative patients were greater among the less
educated. This contention was supported by investigations of the cognitive reserve
hypothesis (van Gorp et al 1994; Picano & Klusman, 1993; Salmon, 1994; Stem, 1994).
The work on cognitive reserve suggests that higher education levels provide a buffer to
loss of functioning, implying that those patients with higher educational levels can lose
more of their cognitive capacity before showing deficits (Picano & Klusman, 1993),
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although this may be accounted for by the low test ceilings on many neuropsychological
measures. Van Gorp et al. (1993) have concluded that although some studies have
shown impairment it is usually not enough to affect daily functioning, but that infected
people with less education are at greater risk for such a loss.
It is not disputed that in late stages of HIV disease individuals encounter a
decline in functioning. The amount of decline is much less clear in the early stages.
Previously cited studies were primarily of subjects in the end stages. With regard to
studies involving subjects in the early, asymptomatic phase o f their illness, for every
investigation which finds deficits early on, there is generally another to dispute it.
Seines et al (1990) offered several possible explanations for these discrepant findings.
First, they noted that in most early studies which reported differences between
asymptomatic HTV seropositive subjects and HTV seronegative subjects, the samples
were very small and differences could have been due to chance. In larger studies
(Goethe et al., 1989; Mauri, Sinforiani, Muratori, Zerboni, & Bono, 1993; McArthur et
al., 1989; Tross et al., 1988), asymptomatic HTV seropositive subjects did not differ
significantly from HTV seronegative controls.
Also, in the early studies, education level was poorly controlled (Seines et al.,
1990). In those studies, the HTV seropositive sample tended to be much less educated
than controls. Heaton, Grant, and Matthews (1986) and Seines et al. (1990) indicated
that educational levels accounted for significant variance in neuropsychological
functioning. Picano and Klusman (1993) asserted that brain reserve capacity (BRC)
may moderate neuropsychological abnormality as HIV disease progresses and may
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partially account for the variability in neuropsychological impairment observed in early
stages of HTV infection. To get an accurate picture of neuropsychological changes
throughout the course of HIV disease one must ensure that the sample size is adequate
and the control group is fairly equally matched to the sample. Finally, it is important to
use tests that have been shown to be sensitive to the deficits that are typical o f HIV
seropositive subjects (Newer, Miller, Visscher, & Satz, 1991).
White and her colleagues also outlined other possible explanations for the
discrepant results including differences in mode of infection of participants and length
of battery of tests. Studies o f intravenous drug users tend to find loss of functions more
often than investigations which look at only gay men. Battery length, they argued,
affects results because brain areas affected by the virus vary between individuals, as do
the difficulties that result. Therefore investigations that compare subjects on only a few
tests will be less likely to find positive results when trying to uncover deficits because
many of the subjects are likely to be impaired in one or more areas that may not be
tested.
Consistent with the report o f White and her coIIeagues(1995), Heaton et al.
(1995), using an 8-hour test battery, compared subjects on the presence or absence of
impairment (defined as below average functioning in 2 or more domains) rather than
comparing subjects in specific areas of functioning. Using this more global definition of
impairment they reported increased rates of impairment at each successive stage o f HTV
infection in their sample o f 500 men. They carefully point out, however, that although
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30.5% o f their subjects evidenced some form of neuropsychological impairment,
almost 70% of subjects did not.
Although the exact timing of deficits has been disputed, it is not questioned
that HIV patients will frequently demonstrate neuropsychological decline as their
illness progresses. Deficits have been mainly characterized as subcortical in nature with
dysfunction in the areas of psychomotor functioning, behavior, memory, and cognitive
performance (Navia et al., 1986b; Price et al., 1988). However, several other areas that
have been investigated have revealed deficits.
Psychological Components. Relatively few studies in the literature have
reported changes in psychological status. Increased depression in HIV seropositive
subjects has been infrequently mentioned (Miller et al., 1990; Poutiainen et al., 1988),
and the majority of studies reported no differences in mood between HIV seropositive
and HIV seronegative subjects (Olio & Pass, 1988; Perdices & Cooper, 1989; van Gorp
et al., 1989). Noting that a typical complaint of HIV seropositive subjects is dysphoria,
van Gorp suggested that negative findings regarding mood may be due to selection bias
in many studies. Perhaps people who were depressed did not volunteer to participate.
Neuropsychological deficits in HTV seropositive subjects, however, cannot be
accounted for by depressed mood (Grant et al., 1993). Likewise, in the area of anxiety,
reports have been sparse.
Neuropsychological Consequences of Anxiety
The topic o f the effect o f emotional state on test performance has been a subject
of considerable investigation. In particular, depression is frequently considered to have
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an impact on performance on neuropsychological tests (Gass & Russell, 1986; Heaton
& Crowley, 1981; Hinkin, et al., 1992; Sackheim, et al., 1992). However, while
depression has been studied for its potential effects, the literature has largely ignored
the investigation o f anxiety as an impediment to test performance.
Even undergraduate psychology majors are familiar with the inverted "U" of
Yerkes and Dodson (1908) in which a graph of test performance follows an inverted
"U" shape when performance is plotted on the y-axis, and anxiety is plotted on the xaxis. At very low levels o f anxiety, performance is poor due to lack of arousal or
motivation. As anxiety increases, arousal increases, and test performance rises
proportionately, but past a certain point the anxiety begins to interfere with
performance by narrowing the focus of attention so that the individual becomes fixated
on certain stimuli while relatively ignoring the rest. Performance then begins to decline
with increasing anxiety.
While the Yerkes-Dodson Law has been demonstrated in the laboratory, and
most people can probably think of examples from their own lives, the study of the
neuropsychological consequences of anxiety has not progressed far beyond this point.
Even in the investigations of anxiety, researchers have typically limited themselves to
the investigation o f specific anxiety disorders - anxiety as a trait- rather than to state
anxiety. Additionally, positive results have typically been reported when using tasks in
which the anxious subjects' attention was drawn to stimuli relevant to their particular
anxiety situation.
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Burgess and colleagues (1981) used a dichotic listening shadowing task to
demonstrate that agoraphobic and social phobic subjects detected a greater number of
target words (words with phobic relevance) presented to the unattended channel than
did controls. Foa and McNally (1986) conducted a similar investigation with obsessivecompulsive patients and achieved corroborating results. These studies provide evidence
for an attentional bias in anxiety disorders.
Other researchers have demonstrated that attention can be drawn away from
ongoing task demands and toward threat cues in the environment (Matthews &
MacLeod, 1986; MacLeod, Matthews, & Tata, 1986). Reaction times to to-be-detected
visual probes were longer if the probe coincided with a threat word in a different
channel (auditory) (Matthews & MacLeod, 1986). In the second study, shorter reaction
times resulted when subjects were required to report the location of a dot on a screen if
the dot appeared in the same place where an anxiety related word had been (MacLeod,
et al., 1986). These, and other investigators have used a modified Stroop task to show
that color naming latency was longer for threat words than for non-threat words (Geller
& Shaver, 1976; Matthews & MacLeod, 1985).
However, it seems that while attentional capacity is preferentially drawn to
threat words over neutral stimuli, researchers have failed to find a threat bias in recall
and recognition trials. In fact, Mogg, Matthews, and Weinman (1987) found that
anxious subjects had a higher recognition rate for non-threat words, than for threat
words.
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While it is not questioned that attention is drawn to anxiety provoking stimuli in
subjects with anxiety disorders, on neuropsychological tests measuring constructs other
than attention, the anxiety disorders appear to play much less o f a role. For example,
Zalewski, Thompson, and Gottesman (1994) failed to find differences between the
performance of veterans with Post Traumatic Stress Disorder, Generalized Anxiety
Disorder, and control veterans on such measures as the Wechsler Adult Intelligence
Scale - Revised (WAIS-R; Wechsler, 1981) Block Design subtest, the California Verbal
Learning Test, the Rey-Osterrieth Complex Figure Test, and the Paced Auditory Serial
Addition Test
Gass, Ansley, and Boyette (1994), however, suggest that state anxiety, rather
than anxiety disorders may be associated with preoccupations, intrusive thoughts,
inattention, distractibilty, and anxiety over possible failure. They have demonstrated
that scores on maze performance and fluency tests (both verbal and non-verbal) are
mildly associated with a measure of GAD and strongly related to a Minnesota
Multiphasic Personality Inventory - 2 measure of fearfulness. Likewise, Buckelew and
Hannay (1986) demonstrated that performance on the Block Design subtest of the
WAIS-R (Wechsler, 1981) and word fluency tests were sensitive to state anxiety and
Mueller, (1979, cited in Lezak, 1983) and Pyke and Agnew (1963) found decreased
abilities on the Digit Span Forward subtest of the WAIS-R in their anxious subjects.
King and colleagues have also shown that lower scores on the Finger Tapping Test and
higher times to completion on the form board were related to higher trait anxiety (King,
Hannay, Masek, & Bums, 1978).
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Impairment in cognitive functioning has been a consistent complaint o f patients
with anxiety disorders, and is even listed as a criterion for the diagnosis o f PTSD
(American Psychiatric Association (APA), 1994). According to the authors cited above,
these complaints may be justified.
Attentional Bias in Anxious Persons
The attentional bias produced by anxiety clearly leads to cognitive deficits, but
it seems equally likely that global deficits may be produced, or at least exaggerated, by
the anxious person due to hypervigilance to any loss. In the medically compromised
patient experiencing even slight cognitive decline, anxiety about the losses may lead to
a misinterpretation o f normal test errors as an indication of decline.
Several investigators have noted the negative impact of mood on appraisal of
cognitive performance in HTV seropositive people. In fact, Perry (1990) reported that
HIV seropositive people's metacognitions indicate that they feel that their deficits are
worse than they actually are measured to be. And van Gorp et al. (1991) reported that
depression is associated with increased cognitive complaints (including forgetting
appointments and experiencing the tip o f the tongue phenomenon), but the number of
complaints is unrelated to actual deficits. Further, Wilkins et al. (1991) reported that
although 49% o f their subjects reported cognitive complaints, the complaints were
associated with psychiatric symptoms (including depression and anxiety), but again, not
with cognitive performance. Van Gorp and colleagues (1993) summarized the relation
o f mood to report o f cognitive complaints stating that subjective report o f cognitive
failures may be more related to an individual's current affective state rather than to
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objective neuropsychological difficulties. However, more recently, Poutiainen and
Elovaara (1996) have clarified this relation with regard to stage of HIV infection,
stating "in symptomatic infection 'subjective' complaints may reflect 'objective'
cognitive deficits, whereas for asymptomatic subjects there may be other reasons for
such complaints," (p. 224). These studies indicate that anxiety may impact appraisal of
performance in situations where it does not directly influence performance.
Hypotheses
The current study will attempt to further elucidate the role that anxiety plays in
the neuropsychological dysfunction in early HIV disease. Given the disparate findings
in the research literature on HIV seropositive people in the early stages of disease, it is
possible that with tighter control over previously uncontrolled variables, a clearer
picture of the neuropsychological sequelae in early HIV disease may emerge;
suggesting that one or another of these variables may have impacted and confounded
previously reported results. One variable that has not received extensive attention in the
HIV literature has been anxiety. Therefore, it is necessary that before the
neuropsychological deficits in HIV disease be attributed directly to the effects of HIV,
the possibility that anxiety plays a role in neuropsychological dysfunction in early HIV
disease must be examined. Hypotheses to be researched in this investigation include: 1)
HIV seropositive participants will evidence significantly lower performance scores on
neuropsychological measures said to be sensitive to HIV serostatus than their HIV
seronegative counterparts, regardless of anxiety level. A main effect is expected for
HTV serostatus for those neuropsychological measures previously shown to be diturbed

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

29
in people with HIV. 2) Participants high in anxiety will perform more poorly on those
tests which are sensitive to increased anxiety (a main effect for anxiety level). 3) An
interaction between HIV serostatus and anxiety level is expected for perfromance
appraisal scores. The participants high in state anxiety will judge their performances on
neuropsychological measures to be lower than their actual scores, and that this
difference will be exaggerated in those individuals with HTV. These findings would
suggest that neuropsychological deficits which are seen early in HIV disease are not due
to anxiety but likely are related to the direct effects of HIV on cognitive functioning,
and that anxious participants would have a tendency to exaggerate their self-report of
the deficits that they do experience.
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Method
Participants
This investigation received approval from the Louisiana State University
Medical Center Institutional Review Boards and the Louisiana State University
Institutional Review Board. Seventy-six participants were recruited from the HTV
Outpatient (HOP) Clinic at Medical Center of Louisiana at New Orleans (MCLNO) in
New Orleans, Louisiana. Thirty-eight clinic patients composed the experimental group,
and the control group was made up of HTV seronegative friends or relatives of HTV
seropositive individuals seen at this clinic (N = 11) or elsewhere (N = 27). This control
group was chosen in order to maximize the similarities to the experimental group in
terms of demographics and anxiety level. No monetary or other compensation was
offered to the subjects. Potential risks (no serious risks) and benefits (aid in future
treatment o f HTV patients) of the study were explained, and participants were instructed
that they could request information on the results of the study, and this information
would be forwarded to them after completion of the study.
Because this study focused on asymptomatic HTV disease, subjects were
excluded if their T-cell count was lower than 200 CD4/mm3 of blood, or if they had
begun to show systemic complications of HIV disease (qualifying for a diagnosis of
AIDS). All HIV seropositive individuals fell into CDC categories A l, A2, B l, or B2.
Potential participants were also excluded if they had abused recreational drugs or
alcohol within the preceding six months, as defined by DSM-IV (APA, 1994) criteria,
or if they were unable to achieve a sixth grade reading level on the Wide Range
30
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Achievement Test Revision Three (WRAT-3; Wilkinson, 1993). Attempts were made
to equate all groups on the basis of race, age, sex, education level, and intellectual
functioning.
Materials
Dependent variables were derived from neuropsychological measures which
were selected because they have been shown to be sensitive to performance decrements
among subjects with HIV or anxiety. The neurocognitive areas selected for assessment
were based on their vulnerability to HTV infection included attention and concentration
(Paced Auditory Serial Addition Test), learning and memory (Rey Auditory Verbal
Learning Test), psychomotor speed (Grooved Pegboard), verbal fluency (Controlled
Oral Word Association Test), and information processing (Trail Making Test Part B).
Neuropsychological measures sensitive to anxiety included tests that are very difficult
or elicit the greatest amount o f state anxiety (Buckelew & Hannay, 1986) (e.g., Block
Design and Digit Span Forward from the Wechsler Adult Intelligence Scale - Revised
and the Paced Auditory Serial Addition Test). Additionally, a measure of anxiety
(State-Trait Anxiety Inventory - State form) was utilized to determine group placement,
and an estimate of intellectual functioning (Shipley Institute of Living Scale) was
employed as a control variable.
A final dependent variable was the accuracy o f the participants appraisal of his
or her neuropsychological functioning. After administration of each of the
neuropsychological measures, subjects were asked to estimate their performance on
that test on a scale o f below average, average, or above average. For each measure, a
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score of -2, -1 ,0,1, or 2 was assigned based on the comparison o f the participant's
appraisal to his or her actual performance level. A score of -2 indicated an appraisal of
below average for an actual above average performance (the subject appraised his or
her performance to be 2 steps below his or her actual performance). Subjects who
appraised their performance one step below their actual performance were given a
score of -1. Correct appraisals obtained a score of 0, while overestimates of actual
ability received scores of 1 or 2 depending on the extent of their overestimates.
Negative appraisal scores were summed and the absolute value of this sum constituted a
dependent variable defined as the extent of the underestimation of his or her
performance (NEGAPP). Likewise, positive appraisal scores were also be summed to
yield a dependent variable for the level of overestimation of performance (POSAPP).
The following measures were used in this investigation.
State-Trait Anxiety Inventory. fSTAI: Spielberger, 1983). The STAI assesses
both level of anxiety symptoms at the time of administration (the state portion, STAIS), as well as the examinee's general level of anxiety (the trait portion, STAI-T). Only
the STAI-S will be used for this study. The STAI-S has been shown to be internally
consistent (median alpha coefficient of .92) and concurrently valid (correlation of .77 to
.84 with other anxiety measures). However, test-retest reliability is low (.16 to .62)
which reflects fluctuation in anxiety states over time (Spielberger, 1983).
Shiplev Institute of Living Scale. (SILS; Shipley, 1946). The SILS is a paper and
pencil test consisting of two parts. The first, the verbal section, is a multiple-choice test
that involves picking from four choices the best synonym for each of the test words.
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The second part is a free response test of abstract reasoning in which the subject must
complete several incomplete series (for example, the subject may be given the series
1,2,3,4,

and will be asked to fill in the blank). The Shipley total score (Verbal and

Abstract quotients) provides estimated WAIS (Wechsler, 1955) and WAIS-R
(Wechsler, 1981) IQ scores and was used as an estimate o f intellectual functioning in
this investigation. Reliability estimates for the Shipley total score range from .78 for
test-retest reliability to .92 for split-half reliability. Although heavily verbally weighted,
the Shipley total score has shown a median correlation of .79 with the WAIS (range of
.73-.90 across 11 studies) and correlations of .74 and .85 with the WAIS-R (Zachary,
1986).
Rev Auditorv-Verbal Learning Test. CRAVLT: Rey, 1964; Lezak, 1983). The
RAVLT involves verbal presentation of a list of fifteen nouns (list A) to the examinee
who is then asked to repeat the list back to the examiner in no particular order (free
recall portion). After five presentations of the list, a second list of fifteen nouns (list B)
is presented as an interference trial, followed by a free recall test o f this list.
Immediately following recall of list B, the original list is requested again to assess
interference. After twenty minutes, free recall of list A is again tested (delayed recall).
The RAVLT is well normed for ages thirteen through above seventy and demonstrates a
test-retest reliability of .55 at one year intervals (Snow, Tierney, Zorzitto, Fisher, &
Reed, 1988). Alternate forms of the RAVLT correlate in the range o f .60 to .77, and in
factor analytic studies, the RAVLT learning measures correlate .50 to .65 with other
learning measures (Lezak, 1995). The RAVLT is generally regarded as a measure of
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episodic verbal memory, and is well-normed nationally as well as regionally using
subjects from Louisiana (Savage & Gouvier, 1992). For the purposes o f this study, the
total recall for trials 1-5 (RAVLTTOT), and the recall on the delay measure
(RAVLTDLAY) were used as dependent variables.
Trail Making Test. Parts A and B. (TMT; Army Individual Test Battery, 1944).
The TMT assesses visuospatial search skills, psychomotor speed, and the examinee's
ability to alternate between cognitive sets within a task (divided attention). The test
involves connecting a series o f circles in numeric order (Part A) and alternating alpha
numeric order (Part B). In part A the circles are labeled with numbers and must be
connected in order from lowest to highest number. Part B employs both numbers and
letters, and the circles are connected in ascending order, alternating between numbers
and letters. Reliability coefficients for the TMT have ranged from .46 to .98 for part A
and .44 to .92 for part B (Spreen & Strauss, 1991). Lower reliabilities were from studies
assessing test-retest reliability in which scores would be expected to improve and
reliabilities would therefore be lower. Higher reliability ratings were from alternate
forms. These findings would seem to indicate strong practice effects. The TMT has
been found to be highly sensitive in detecting brain damage (Dodrill, 1978; O'Donnell,
1983). The test yielded 2 dependent variables, TMTA, which was the time to
completion for Part A of the TMT, and TMTB, the time to completion for Part B of the
TMT.
Block Design. (BD; Wechsler, 1981). This test involves the use o f cubes that are
red on two sides, white on two sides, and half red and half white on two sides. The
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participant is first given four cubes to replicate specific designs. As the test progresses
in difficulty, the participant is given nine blocks to construct more complex designs.
Split-half reliability ranges from .83 for 55-64 year old participants to .89 for
participants aged 25-44. The BD test has also been shown to be sensitive to high levels
o f anxiety (Buckelew & Hannay, 1986). The participant is given 2 chances to correctly
replicate each of the first 2 designs, and is given 2 points for a correct response on the
first attempt, and 1 point for a correct response on the second attempt. The participant
receives at least 4 points for each design correctly replicated after the initial 2 designs.
Partial credit is not given, however, bonus points are added for speed of performance.
The dependent variable (BLOCKS) obtained from this measure represented the
participant’s total score on the measure.
Grooved Pegboard Test. (GPT; Klerve, 1963; Matthews & Klove, 1964). This
test requires fitting ridged pegs into a board containing a five by five grid of slotted
holes rotated at various angles. Normally the time to completion for each hand is
scored. The GPT assesses motor slowing or clumsiness and provides measurements for
both the dominant and non-dominant hands (Miller et al., 1990). Kelland and
colleagues (1992) found substantial test-retest reliability (r=.82) with this measure. This
test also yielded two dependent variables, GPTD, the time required to complete the test
using the participant’s dominant hand, and GPTN, the time to completion using the
non-dominant hand.
Digit Span Forward. (DSF; Wechsler, 1981). On this test that is generally
regarded as a measure sensitive to attention and concentration, the examiner reads
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aloud a series of digits at a rate o f one per second. After the last digit in the series has
been read, the participant must repeat the digits to the examiner in the exact order in
which they were presented. The number of digits presented increases as the test
progresses. The participant is given 2 chances to correctly repeat a sequence at each of
the specified string lengths. For each string that is correctly repeated, the participant is
awarded 1 point. The second attempt at each string is administered and scored
regardless of the participant’s success or failure on the first attempt. The test ends when
the participant fails to correctly repeat both strings at a given length. Split-half
reliability coefficients range from .70 for 16-17 year olds to .89 for 25-34 year olds.
Performance on the DSF has been shown to be sensitive to anxiety (Mueller, 1979 cited
in Lezak, 1995; Pyke & Agnew, 1963), and is generally not affected in persons with
HIV disease (Miller et al., 1990). The participant’s score was the number of strings of
digits correctly repeated. This score constituted the DIGITS variable for this
investigation.
Controlled Oral Word Association Test. (FAS Test; Benton & Hamsher, 1976;
Benton et al., 1983). The FAS test is a measure of word fluency or word production.
The examinee is given one minute to generate as many words as possible that begin
with a specified letter. The letters F, A, and S are most often chosen and will be used
for this study. The FAS Test has shown high test-retest reliability ranging from .70 at
one year (Snow et al., 1988) to .88 at 19-42 days (desRosiers & Kavanagh, 1987). The
FAS Test is well normed and is sensitive in identifying frontal and prefrontal brain
damage (Spreen & Strauss, 1991). The dependent variable FAS obtained from this
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measure corresponded to the total number of words produced by the participant using
all three letters.
Paced Auditory Serial Addition Test. (PASAT; Gronwall, 1977). The PASAT
has been used to assess sustained attention and concentration, as well as information
processing. The test involves auditory presentation to the examinee of a series o f digits.
The participant adds each presented digit to the preceding one, saying the sum aloud.
The PASAT has shown excellent internal consistency with a split-half reliability
measure o f .96 (Egan, 1988). Spreen and Strauss (1991) have described the PASAT as a
"very sensitive test of deficit in mildly brain-injured people," (p. 148). Because the test
is "quite demanding" even for non-injured subjects (Spreen & Strauss, 1991; p. 148), a
shortened version developed and normed by Rao, Leo, Bemardin, and Unverzagt (1991)
in which digits are presented at 3 second intervals, then at 2 second intervals was used.
The score obtained from this measure (PASATTOT) was the sum of the number of
correct responses given on the two trials.
Procedure
Following the receipt of informed consent, all participants were administered
the WRAT-3 reading test to determine eligibility for the investigation. The participants
next completed a short demographic information sheet, and the remaining measures
were administered to all subjects in the following order:
1) STAI-S
2) SILS
3) RAVLT (free recall portion)
4) TMT Parts A and B
5) Block Design

6) GPT
7) Digit Span Forward
8) RAVLT Delay
9) FAS Test
10) PASAT
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The testing order was the same for all subjects because their performances were
compared against one another, and the study was not intended to examine specific
deficits within domains of functioning. Therefore, the effects of order of presentation
were not assessed. The STAI-S was administered first in order to obtain a measurement
of the subjects’ anxiety levels as testing began. Next, the SILS was administered
because the score on this test was used as a control variable. The RAVLT was the first
neuropsychological measure administered because it contains a built in delay that must
be administered later in the session. The TMT parts A and B , Block Design, GPT, and
Digit Span followed next in order to fill the time between the RAVLT free recall and
delayed recall with non-verbal tests that would not interfere with memory of the word
list for the RAVLT. Next, the RAVLT delayed recall test was administered due to the
constraint that it must follow the free recall portion by 20 minutes. The FAS test
followed in order that the PASAT might be administered last due to the high rate of
failure on this test and the increased anxiety and discomfort it can engender. The order
of testing was chosen to maximize efficiency, gathering the greatest amount of
information in the least amount of time while minimizing subject fatigue.
The 1-1.5 hour battery was administered in a single setting. To decrease the
likelihood o f fatigue, a two minute break was offered after the RAVLT delayed recall
was completed. No breaks were given before that point, as the time between initial
administration o f the RAVLT and the delayed recall test is fixed at 20 minutes. Testing
was administered with the examiner sitting across a desk from the subject in a room
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with adequate lighting that was relatively free o f distractions. As stated above, after
administration of each measure performance appraisals were obtained.
Three examiners were used for this investigation. All examiners were familiar
with the administration o f psychological measures, and used a standardized instruction
sheet which is reproduced in Appendix D.
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Results
The sample size for the current study totaled 76 participants, 38 o f whom were
HIV seropositive, and 38 seronegative individuals. Of the participants, 58 (76.3%) were
white, 17 (22.1%) were African-American, and 1 (1.3%) was Native American. For the
purposes of the investigation, the latter two groups were combined to yield race
categories of white, and non-white. Sixty-two (80.5%) participants were male, and 14
(18.2%) were female. The ages o f participants ranged from 19-53 years, with a mean
age for participants o f 34.5 years (SD = 7.4 years). The mean education level was 15.0
(SD = 2.2 years), with a range o f 11 - 20 years. The mean age- and sex- corrected STAIS T-score for all participants was 48.7 (SD = 8.2), indicating that the anxiety level for
the sample was in the average range when compared to the normative data for the
measure.
Of the 38 participants with HIV disease, 26 (65.8%) were prescribed (and
reported taking) one or more anti-retroviral medications (including reverse transcriptase
inhibitors as well as protease inhibitors). Twelve (34.2%) reported that they either had
not been prescribed medication, or had chosen not to take those that had been
prescribed. The mean CD4 count for the HTV seropositive participants was 443.4
CD4/mm3 (SD = 175 CD4/mm3), and ranged from 210 - 982 CD4/mm3. For a listing of
demographic information, please see Table 2.
For the first set of analyses, only those subjects whose STAI-S score fell in the
highest one third of all scores or the lowest one third of all scores were included in the

40
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Table 2
Demographic Information for the Entire Sample and for Each of the HIV Serostatus
Subgroups.___________________________________________________________
Variable

Entire Sample

HIV +

HIV-

White
Non-white

58
18

26
12

32
6

Male
Female

62
14
34.5 yrs.
15.0 yrs.
48.7
N/A

32
6
34.3 yrs.
14.1 yrs.
50.3
443.4CD4/mm3

30
8
34.7 yrs.
15.9 yrs.
47.1
N/A

N/A
N/A

26
12

N/A
N/A

Race

Sex

Age
Education
STAI-S T-score
CD4 count
Medication status
Yes
No

analyses. Therefore, only participants scoring 51 or higher, or 45 or lower on the STA1S were utilized. When the two groups were further divided according to their HTV
serostatus, four groups were created. In order to increase the number of participants
included in the analyses, for those participants with missing PASATTOT scores (N =
4), the overall sample average PASATTOT score of 83 for the entire sample was
substituted in place of the missing data. The groups were: low anxious - HIV
seronegative (N=13), low anxious - HIV seropositive (N=8), high anxious - HIV
seronegative (N=l 1), and high anxious - HIV seropositive (N=17). Chi-squared tests
were conducted on these four groups to determine group equality in terms of race and
sex, and these were found to be non-significant (for X2 values and significance levels
please refer to Table 3).
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Table 3
X2 Values Comparing HIV Seropositive and HIV Seronegative Participants at High and
Low Anxiety Levels as Determined Using a Tertile Split of Anxiety Scores.__________
Variable

Anxiety Level

x-

Significance

df

RACE

Low
High

0.50
3.02

A ll
.082

1
1

SEX

Low
High

0.03
0.22

.854
.636

1
1

To determine group equality for the control variables age, education, and
Shipley total score, 2 X 2 ANOVA’s were performed using the scores on these tests as
dependent variables. The groups did not differ significantly in terms of age of
participants or Shipley total score. However, ANOVA revealed a main effect for HIV in
terms of years of education with the HTV seronegative subjects being more educated
(mean = 16.2 years) than those infected with HIV (mean 14.2 years), F(2,48) = 9.46, p <
.01. Therefore, in subsequent analyses involving these groups, education was entered as
a covariate to control for any confounding effects.
Multivariate analysis o f covariance (MANCOVA) used to examine group
differences on the measures that assess areas that have been shown to be disturbed in
patients with HTV revealed no significant two-way interactions, or main effects. While
examination of univariate tests does not typically follow a non-significant MANCOVA,
for the purposes o f this investigation, the univariate results will be reported to highlight
areas which may be important to investigate in future endeavors o f this nature.
Examination of the univariate tests, revealed a significant two-way interaction for the
RAVLT total score (F(l,43) = 2.33, p < .02) in which those participants in the high
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anxious - HIV seropositive group scored significantly more poorly (mean = 41.2, SD =
7.4) than participants in the low anxious - HIV seropositive group (mean = 51.1, SD =
4.0). Differing anxiety levels led to differences in scores, but only for those participants
with HIV. In addition, a main effect was observed for anxiety on the time to complete
the Trail Making Test part B (F(l,43) = 4.34, p < .05). Group means indicated that
those participants in the high anxiety groups required longer times to complete the
measure than patients in the low anxiety group regardless of their HIV serostatus.
A MANCOVA performed on those variables that are frequently disturbed in
anxious participants again revealed neither a significant two-way interaction, nor a
significant main effect for either anxiety or HTV serostatus. Examination o f the
univariate tests revealed a significant main effect for anxiety level on the Block Design
variable (F(l,44) = 4.06, p = .05). Inspection of the group means indicated that those
participants in the high anxiety groups performed more poorly on the measure than
those with less anxiety, regardless of their HIV serostatus. For group mean scores on
each of the measures administered, please see Table 4.
The next set of analyses utilized scores from all participants. The participants
were again divided into four groups depending on their STAI-S scores, and their HTV
serostatus, and again the overall sample mean was substituted for all missing
PASATTOT scores. For the following analyses, however, a median split at the STAI-S
T-score of 48 divided the participants into low and high anxiety groups. The resulting
groups were: low anxious - HTV seronegative (N=21), low anxious - HTV seropositive
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Table 4
Mean Test Scores (and Standard Deviations) for each Group (as Created Using a Tertile
Split o f STAI-S Scores and HTV Serostatus) on Dependent Measures._______________
Group
Measure

Lo Anx/HIV- Hi Anx/HIV- Lo Anx/HIV+ HiAnx/HTV+

51.1 (4.0)*
41.2 (7.4)*
47.2 (9.3)
47.5 (4.6)
RAVLTTOT
9.4 (3.3)
RAVLTDLAY
9.4 (2.9)
10.0(1.8)
7.2 (3.2)
42.7 (12.2)
44.5(10.7)
44.8 (10.4)
37.6 (9.9)
FAS
64.0 (12.4)
66.4 (8.5)
64.8 (6.4)
75.3 (16.0)
GPTD
71.7(11.0)
69.0
(12.4)
71.2(12.4)
81.1 (18.9)
GPTN
83.9(19.1)
82.9 (22.4)
83.6(12.5)
75.4 (23.0)
PASATTOT
22.7 (6.2)
22.5 (7.2)
23.6(6.1)
26.0 (8.9)
TMTA
51.9 (16.4)** 54.4 (20.7)
49.1 (14.0)** 69.9 (20.3)
TMTB
34.5(10.1)** 32.7 (8.9)
38.2 (7.4)** 26.4 (9.6)
BLOCKS
8.1 (2.7)
8.4 (2.6)
9.1 (1.3)
7.1 (2.3)
DIGITS
Note. Lo Anx/HIV- = Low anxiety - HTV seronegative group; Hi Anx/HTV- = High
anxiety - HIV seronegative group; Lo Anx/HIV+ = Low anxiety - HIV seropositive
group; Hi Anx/HIV+ = High anxiety - HTV seropositive group.
* = Indicates the two groups significantly different within the significant interaction.
** = Indicates a main effect with the two groups with highest scores marked with (**).
(N=18), high anxious - HTV seronegative (N=17), and high anxious - HTV seropositive
(N=20).
Chi-squared tests were performed for these groups on the control variables race
and sex were found to be non-significant, indicating that there were no group
differences on these variables (see Table 5). The data were then subjected to 2 X 2
ANOVA's for the variables age, education level, and Shipley total score. As before,
ANOVA's for age and Shipley total score were not significant, a main effect for HIV
was again found with regard to education level (F(l,75) = 15.00, p < .001) with the HTV
seropositive participants being less educated (mean = 14.11 years) than the HIV
seronegative participants (mean = 15.92 years). As with the previous set of analyses,
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Table 5
X2 Values Comparing HIV Seropositive and HTV Seronegative Participants at High and
Low Anxiety Levels as Determined Using a Median Split of Anxiety Scores._________
Variable

Anxiety Level

A2

Significance

df

RACE

Low
High

1.04
1.80

.308
.179

1
1

SEX

Low
High

0.47
0.07

.493
.795

1
1

education was therefore used as a covariate for all analyses using these groups.

As

with the previous set of analyses, the scores on the measures that are often disturbed in
patients with HTV were subjected to a 2 X 2 MANCOVA. Again, the MANCOVA was
not significant for the two-way interaction, or for main effects for anxiety or HTV
serostatus. Examination o f the univariate tests revealed no significant group
differences.
Next, a MANCOVA was performed on the scores for the measures thought to
be sensitive to differences in anxiety level. This MANCOVA was also non-significant
for the two-way interaction as well as for main effects for anxiety and HTV serostatus.
Again, the univariate tests were not significant Group mean scores for each of the
variables are listed in Table 6.
Finally, the two HIV groups were compared to determine whether they differed
in terms of their anxiety levels. While the ANOVA on these groups did not indicate a
significant difference, the difference did approach significance (F(l,75) = 3.00, p <
.09). For that reason, the variables most often found to be sensitive to HIV serostatus
were entered into a one-way MANCOVA with education and STAI-S scores entered as
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Table 6
Mean Test Scores (and Standard Deviations) for each Group (as Created Using a
Median Split o f STAI-S Scores and HIV Serostatus) on Dependent Measures.

Group
Measure

Lo Anx/HTV- Hi Anx/HTV- Lo Anx/HTV+ Hi Anx/HTV+

42.5 (7.5)
49.0 (6.0)
48.6 (8.8)
RAVLTTOT
49.0 (8.8)
7.6 (3.1)
9.6 (2.9)
9.5 (2.4)
RAVLTDLAY
9.8 (2.9)
38.9(10.9)
44.0
(12.2)
43.2
(9.2)
42.1
(12.0)
FAS
73.5(15.5)
65.5 (6.2)
68.5(14.6)
66.6 (8.4)
GPTD
73.5(12.4)
80.3 (18.7)
71.0(10.6)
74.0(15.8)
GPTN
82.0 (20.7)
84.0(19.4)
75.8(21.2)
89.3 (18.9)
PASATTOT
25.0
(8.7)
21.9(6.6)
22.4 (6.5)
24.4 (6.8)
TMTA
66.6 (20.2)
52.4(14.1)
53.5 (21.3)
58.7(31.6)
TMTB
34.4 (9.3)
26.8 (9.8)
35.2(10.2)
35.2(11.2)
BLOCKS
7.4 (2.3)
8.7 (1.6)
8.7 (2.6)
8.3 (2.8)
DIGITS
Note. Lo Anx/HIV- = Low anxiety - HTV seronegative group; Hi Anx/HIV- = High
anxiety - HIV seronegative group; Lo Anx/HTV+ = Low anxiety - HIV seropositive
group; Hi Anx/HIV+ = High anxiety - HTV seropositive group.
covariates in order to examine differences between the HTV serostatus groups when
their anxiety level was held constant. This MANCOVA was also found to be non
significant, as were the univariate follow up tests. For group means on dependent
variables for each of the HTV groups, please see Table 7.
The second part of the study used the positive and negative appraisal scores
derived from the participants' assessments o f their performances. As described above,
these scores were computed by asking the participant to rate his or her performance on
a scale o f below average, average, or above average. These judgments were then
compared to their actual performance in relation to all other participants. From these
appraisals, two scores were determined, the extent to which the participant
underestimated his/her performance (NEGAPP) which was the absolute value of the
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Table 7
Mean Test Score (and Standard Deviations) by HIV Serostatus Group on Dependent
Measures, Controlling for Anxiety Level.______________________ ______ _____
— --- -------------

Group
Measure
RAVLTTOT
RAVLTDLAY
FAS
GPTD
GPTN
PASATTOT
TMTA
TMTB
BLOCKS
DIGITS

HIV seropositive
45.4 (8.6)
8.5 (2.9)
40.5(11.4)
71.1 (15.1)
77.2(17.4)
79.8 (20.4)
24.8 (7.7)
62.8 (26.3)
30.8(11.2)
7.8 (2.5)

HIV seronegative
49.0 (7.6)
9.7 (2.8)
43.6(10.8)
66.1 (7.4)
72.1 (11.3)
86.1 (19.8)
22.2 (6.5)
52.9(17.5)
34.8 (9.7)
8.7 (2.2)

sum of his/her under appraisal scores, and the extent to which the participant
overestimated his/her performance (POSAPP) defined as the sum of his or her over
appraisal scores.
Two by two ANOVA's were used to determine if the four groups differed in the
accuracy of their performance appraisals. The first two ANOVA’s were performed on
the NEGAPP and POSAPP scores of the groups defined by the tertile split (participants
at the extreme anxiety levels). The second set of ANOVA's was conducted to determine
if the groups determined by the median split of STAI scores differed significantly on
NEGAPP or POSAPP scores. None of the ANOVA's were significant, indicating that
neither a participant's HIV serostatus, nor his/her anxiety level was related to his/her
ability to accurately judge his/her performance. For NEGAPP and POSAPP scores for
these groups please see Tables 8 and 9.
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Table 8
Mean appraisals scores per group (as Created Using a Tertile Split of Anxiety Score
and HTV Serostatus).___________________________________________________

Group
Variable

Lo Anx/HIV- Hi Anx/HTV- Lo Anx/HIV+ Hi Anx/HIV+

2.38
3.00
2.13
1.76
NEGAPP
1.54
1.18
1.13
1.94
POSAPP
Note. Lo Anx/HIV- = Low anxiety - HTV seronegative group; Hi Anx/HTV- = High
anxiety - HIV seronegative group; Lo Anx/HTV+ = Low anxiety - HTV seropositive
group; Hi Anx/HTV+ = High anxiety - HIV seropositive group.
Table 9
Mean appraisals scores per group (as Created Using a Median Split of Anxiety Score
and HTV Serostatus).____________________________________________________
Group
Variable

Lo Anx/HTV- Hi Anx/HTV- Lo Anx/HTV+ Hi Anx/HIV+

2.57
3.12
NEGAPP
2.22
2.05
POSAPP
1.71
1.06
1.39
1.65
Note. Lo Anx/HIV- = Low anxiety - HTV seronegative group; Hi Anx/HIV- = High
anxiety - HTV seronegative group; Lo Anx/HTV+ = Low anxiety - HIV seropositive
group; Hi Anx/HTV+ = High anxiety - HIV seropositive group.
The final analysis was performed to test for medication effects, therefore only
scores for those participants with HIV were utilized. The HTV seropositive participants
were divided into two groups based on whether they followed a medication regimen
(for HTV) or not. In order to increase the number of cases utilized for the analysis, for
any participant who did not complete the PASAT (N = 3), the average PASAT total
score for HTV seropositive patients (80) was entered as his/her score. A MANOVA
comparing scores from participants who reported taking HTV medications with those
who did not on variables that are reportedly disturbed in HTV seropositive patients was
not significant. Examination of the univariate tests revealed a significant effect for
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medication status for the variable GPTD (F( 1,35) = 5.24, p < .03). Groups means
indicated that those participants taking medication were slower to complete the
Grooved Pegboard Test than the patients who were not taking medication. These results
indicate that for this sample, participants on medication did not perform significantly
differently from those who were not. Mean scores on the dependent variables for the
medicated and nonmedicated groups are listed in Table 10.
Table 10
Mean Scores (and Standard Deviations) for Each Dependent Variable for Medicated
Versus Nonmedicated HTV Seropositive Participants.__________________________
Group
Measure

Medicated

Nonmedicated

RAVLTTOT
RAVLTDLAY
FAS
GPTD
GPTN
PASATTOT
TMTA
TMTB

44.1 (9.4)
8.1 (3.0)
38.6(12.3)
74.6(16.0)
79.7(19.5)
77.6 (20.4)
25.3 (8.7)
65.7 (29.7)

48.7 (5.4)
9.4 (2.6)
45.0 (7.6)
62.8 (8.6)
71.4 (9.7)
85.4 (18.5)
23.4 (4.7)
55.7(14.3)

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

Discussion
Although it would be difficult to find anyone with knowledge in the field to
dispute the evidence of brain dysfunction in late stage HTV disease, such findings are
much less clear in patients early in the disease process. The literature on
neuropsychological functioning in patients with asymptomatic HTV disease is widely
discrepant, and opinions on the merits of the investigations published, as well as the
validity of the results are divergent Many prominent researchers have joined the debate
on both sides o f the issue.
A number of investigations have been published in support of each o f the
positions, and several theories have been advanced to explain the varied results. Some
researchers blame inadequate study design for an inability to find positive results.
Others have suggested that many o f the tests used are not sensitive enough to detect the
subtle deficiencies of which patients with HIV complain. Finally, some investigators
have pointed to the notion that areas of deficits differ across individuals, and pooling of
test scores leads to the lack o f positive findings.
The current study was designed with the intention of ruling out at least one of
the possible explanations for differences between HTV seropositive and HTV
seronegative individuals on neuropsychological measures. To date, no studies have
been published in which possible differing anxiety levels between HTV seropositive and
HIV seronegative participants have been addressed. Given the literature that test
performance can be affected by extreme anxiety, it seems possible that this variable
could influence test performance in patients with HTV. It was the intention o f this study
50
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to demonstrate that disturbed performance on neuropsychological tests in HIV
seropositive participants could not be accounted for by differing anxiety levels, and was
in fact due to differences in HTV serostatus.
In this investigation, the HIV seropositive and seronegative groups did not differ
in terms of their performance on the neuropsychological tests administered.
Additionally, the anxiety level for the two groups was not significantly different.
However, while they did not differ significantly in terms of their level of anxiety, the
difference did approach significance. For that reason, their neuropsychological test
performance was compared while controlling for any differences that may have been
due to anxiety. In fact, any differences between their performance on the
neuropsychological measures was even less obvious under these conditions. These
results would seem to indicate that on the basis of this investigation, anxiety cannot be
ruled out as a contributor to neuropsychological deficits found in previous
investigations, but it cannot be identified as a contributor either because the results
were unchanged under differing anxiety conditions.
To more thoroughly investigate the possible role of anxiety in contributing to
disturbance in neuropsychological functioning in HIV patients, four groups were
created based on scores on the STAI-S and the participants' HIV serostatus. It was
expected that for those tests that in previous studies had evidenced disturbed
performance in HTV patients, a main effect for HIV serostatus would be observed.
Additionally, for those tests which have been demonstrated to be sensitive to anxiety
level, a main effect for level o f anxiety was anticipated. Finding these results would
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have indicated that neuropsychological deficits in HIV patients are in fact related to
differing serostatus regardless of anxiety level. This claim would have been bolstered
by a main effect for anxiety level on the anxiety sensitive tests which would have
shown a dissociation between neuropsychological deficits due to HIV and those related
to anxiety.
The anticipated results, however, were not realized. When the groups were
defined by a median split of scores on the STAI-S, MANCOVA’s on both the measures
thought to be sensitive to anxiety level and those thought sensitive to HIV serostatus
were not significant for the interaction between anxiety level and HIV serostatus, or for
main effects. Likewise, when the groups were chosen to maximize the difference
between the anxiety levels (by taking the top and bottom tertiles), the same
MANCOVA's were again found to be non-significant. The only differences that were
found were on individual tests in the groups representing the extreme anxiety levels.
The tests on which significant differences were found were the Block Design subtest of
the WAIS-R and the Trail Making Test Part B (on which the participants high in
anxiety level performed more poorly), and the total number of words recalled on the
RA.VLT, which highly anxious participants performed more poorly, but only in the HIV
seropositive condition. Again, it would seem that from the results obtained in this
investigation, anxiety cannot be ruled out as a contributor to differences in
neuropsychological test performance between HIV serostatus groups.
The final hypothesis investigated in this study involved the participants'
appraisals of their performances. It was thought that those participants who were most
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anxious would be more likely to judge their performance to be lower than the actual
level, and that this effect would be most pronounced in the HIV seropositive
participants. The test of this effect was also found to be non-significant. It is unclear if
the assumption was invalid, or if the method of investigation was faulty. For this study,
the participants were asked to appraise their performances on the measures given, but,
as many complained, they had no frame of reference for the measures because they
were unfamiliar with the tests. Perhaps a better strategy which may have been more
likely to yield positive results would have been to ask not how they felt about their
performance on specific tests, but to estimate their abilities in the areas tested.
The question remains why the anticipated main effects for neuropsychological
performance were not found in this investigation, and what could be changed in future
research efforts to more accurately examine this population. One problem that likely
plagued this research as it does many other projects was the influence of selection bias.
It is impossible to determine to what extent the data collected were influenced by
differences in those people who volunteered to participate, versus those who refused. It
is very likely that those patients who felt that they had begun to experience cognitive
losses may have been more reluctant to have this suspicion confirmed, and still others
may have been less willing to participate due to extreme anxiety invoked by the testing
situation. In fact, these were the explanations offered by several clinic patients who
chose not to participate. Ironically, the inclusion of these people would very likely have
strengthened this investigation.
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Additionally, one might argue that the number o f participants in this
investigation was inadequate to provide significant results. Although this criticism is
valid, and observed power levels were low, it is important to note that when the F
values and significance levels for the MANCOVA's were examined, the F values were
found to be very small, and the probability levels very high. These statistics indicate
that while the group means were in the predicted directions, the effect size for the
effects under investigation were sufficiently small that even if enough subjects had
been recruited to find significance with adequate power, the results would not have
been any more meaningful in terms of clinical relevance.
One of the requirements for participation in this project was the ability to read
at a sixth grade level. For that reason, several potential participants were excluded from
this study, and others refused to participate when they realized that their reading level
would be assessed. Given the data that differences in neuropsychological test
performance between HTV seropositive and FIIV seronegative participants are most
often seen in less educated patients, the exclusion o f this group was a shortcoming of
this investigation. The lack o f positive results in this investigation seems to support
previous findings of a protective effect for higher education levels against cognitive
loss (Motimer & Graves, 1993; Stem, et al., 1994; Zhang, et al., 1990).
Finally, the majority of the HIV seropositive participants in this investigation
reported following a regimen o f anti-viral medication. Additionally, because the HOP
Clinic at Medical Center of Louisiana is an AIDS Clinical Trials Unit, of those on
medication, all but two had been prescribed protease inhibitors, the newest class of
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anti-retroviral medication. Because of the novelty of these drugs, they have not received
the investigative attention of older medications. It is known that these medications,
alone and, more frequently, in combination with reverse transcriptase inhibitors, can
drop the level of viral RNA copies (viral load) in a patient's blood to undetectable levels
(Cohen, 1996; Deeks, Smith, Holodniy, & Kahn, 1997). While this has been associated
with improved physical functioning and longer survival time (Cohen, 1996, Deeks et
al., 1997), it remains to be seen if this improvement translates into improved cognitive
functioning as well (although this is likely given the documented improvement in
cognitive function associated with other anti-retroviral medication (Portegies et al.,
1993; Portegies et al., 1989; Schmitt et al., 1998; Sidtis et al., 1993)). Given that the
MANOVA comparing those participants taking medication to those participants who
were not was nonsignificant, it is impossible to point to either a positive or negative
effect for medication in the HTV seropositive participants. However, when group mean
scores were considered, the mean scores for all measures for the medication groups
were lower (though not significantly) than their nonmedicated counterparts. A possible
explanation for this unexpected finding is that the subjects on medication were the least
healthy (while viral load estimates were not available, the mean CD4 count of the
medication groups was lower than that of the nonmedicated group, though not
significantly) and they therefore did not perform as well as the nonmedicated group.
Also, given the lack of research on the protease inhibitors, it is possible that they could
in some way have adversely affected the performance of these participants due to an
unreported toxic side-effect of the medication.
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Given the criticisms outlined above, several suggestions present themselves as
ways to improve upon the design of the study. If the study had been funded by an
outside agency, it would be possible to pay potential subjects, which would likely
increase participation. The desire for monetary compensation was voiced most often by
female clinic patients, although it was a consideration for many other potential
participants regardless of their gender. If the investigator were able to pay the
participants, the question of selection bias would not have been removed, but it more
than likely would have been lessened, and a greater number of participants might have
been recruited leading to a wider range of anxiety levels as well as cognitive abilities.
Finally, any investigation of this type must control for medication effects. As
protease inhibitors become more widely available, their potential effects on cognitive
functioning will be better described. With this knowledge, investigators will be better
able to design their research projects to take into account these effects.
The results of this investigation failed to rule out the possibility that anxiety
may contribute to deficits in cognitive functioning in HTV seropositive patients, nor did
it confirm this possibility. Although the stated goal of the project was to rule out a role
for anxiety, it is important to note that regardless of the reason for these deficits, many
patients continue to complain of subtle changes in their cognitive abilities, and these
complaints should be taken seriously. This investigation does, however, point to
specific improvements that can be made for future research endeavors, and highlights a
need for further investigation, especially in the area of medication effects o f the newer
classes of anti-retroviral medication.
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Appendix A
CDC (1992) Category A Conditions
- Asymptomatic HIV infection
- Persistent generalized lymphadenopathy
- Acute primary HTV infection with accompanying illness or history of acute HIV
infection
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Appendix B
CDC (1992) Category B Symptoms:
Attributed to or Requiring Management Complicated by HIV
- Bacillary angiomatosis
- Candidiasis, oropharyngeal (thrush)
- Candidiasis, vulvovaginal; persistent, frequent, or poorly responsive to therapy
- Cervical dysplasia (moderate or severe)/cervical carcinoma in situ
- Constitutional symptoms, such as fever (38.5 C) or diarrhea lasting more than one
month
- Hairy leukoplakia, oral
- Herpes zoster (shingles), involving at least two distinct episodes or more than one
dermatome
- Idiopathic thrombocytopenic purpura
- Listeriosis
- Pelvic inflammatory disease, particularly if complicated tubo-ovarian abscess
- Peripheral neuropathy
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Appendix C
Conditions Included in the 1993 ADDS
Surveillance Case Definition (CDC, 1992)
- Candidiasis of bronchi, trachea, or lungs
- Candidiasis, esophageal
- Cervical cancer, invasive
- Coccidioidomycocis, disseminated or extrapulmonary
- Cryptococcosis, extrapulmonary
- Cryptosporidiosis, chronic intestinal (> I month's duration)
- Cytomegalovirus disease (other than liver, spleen, or nodes)
- Cytomegalovirus retinitis (with loss of vision)
- Encephalopathy, HIV - related
- Herpes simplex: chronic ulcer(s) (> 1 month’s duration); or bronchitis, Pneumonitis, or
esophagitis
- Histoplasmosis, disseminated or extrapulmonary
- Isosporiasis, chronic intestinal (> I month's duration)
- Kaposi's sarcoma
- Lymphoma, Burkitt's (or equivalent term)
- Lymphoma, immunoblastic (or equivalent term)
- Lymphoma, primary, of brain
- Mycobacterium avium complex or M. kansasii, disseminated or extrapulmonary
- Mycobacterium tuberculosis, any site (pulmonary or extrapulmonary)
- Mycobacterium, other species or unidentified species, disseminated or extrapulmonary
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- Pneumocystis carinii pneumonia
- Pneumonia, recurrent
- Progressive multifocal leukoencephalopathy
- Salmonella septicemia, recurrent
- Toxoplasmosis of brain
- Wasting syndrome due to HTV
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Appendix D
Instructions to Examiners
Words in all capital letters are spoken by the examiner. Please remember to obtain a
performance appraisal after each of the dependent variables (refer to Performance
Appraisal Sheet for instructions).

1. Wide Range Achievement Test Reading - Present the reading list to the subject and
say: LOOK AT EACH OF THESE WORDS CAREFULLY (point). READ THE
WORDS ACROSS THE PAGE SO I CAN HEAR YOU. WHEN YOU FINISH THE
FIRST LINE, GO TO THE NEXT LINE AND SO ON. Allow 10 seconds for the
subject to respond. If he/she is in the middle of a response allow him/her to continue. If
there is no response, say: TRY THE NEXT ONE PLEASE. After the first error, the
individual should be asked to repeat the word which was missed. If the word is said
correctly, score as correct. No other help should be given. Do not ask the subject to
repeat any other words unless you could not hear the subject. In that case say: I COULD
NOT HEAR YOU CLEARLY. PLEASE SAY THE WORD AGAIN JUST AS YOU
DID THE FIRST TIME. For this study, the subjects need only correctly read 22 words
before missing 10 in a row. If they miss 10 in a row before correctly reading 22 they
may not be included in the sample. Do not count off if the person has poor diction, or if
the error can be attributed to his/her dialect. Circle the number before each item
pronounced correctly, and draw a line through the first letter of each word pronounced
incorrectly.
74
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2. CES-D - CIRCLE THE NUMBER FOR EACH STATEMENT WHICH BEST
DESCRIBES HOW OFTEN YOU FELT THIS WAY DlJRrNG THE PAST WEEK.

3. Self-Evaluation Questionnaire (State) - A NUMBER OF STATEMENTS THAT
PEOPLE HAVE USED TO DESCRIBE HOW THEY FEEL ARE GIVEN BELOW.
READ THE STATEMENTS BELOW AND INDICATE HOW YOU FEEL AT THE
MOMENT BY CIRCLING THE APPROPRIATE NUMBER.

4.Shiplev Institue o f Living Scale - P art I IN THE TEST BELOW, THE FIRST WORD
IN EACH LINE IS PRINTED IN CAPITAL LETTERS. OPPOSITE IT ARE FOUR
OTHER WORDS. CIRCLE THE ONE WORD WHICH MEANS THE SAME THING.
OR NEARLY THE SAME THING AS THE FIRST WORD. IF YOU DONT KNOW,
GUESS. BE SURE TO CIRCLE TEH ONE WORD IN EACH LINE THAT MEANS
THE SAME THING AS THE FIRST WORD. The subject is given ten minutes or until
he/she indicates that he/she is finished to complete Part I. Part H COMPLETE THE
FOLLOWING BY FILLING DMEITHER A NUMBER OF A LETTER FOR EACH
DASH. DO THE ITEMS IN ORDER, BUT DONT SPEND TOO MUCH TIME ON
ANY ONE ITEM. Again the subject is given ten minutes or until he/she indicates that
he/she is finished.

5. Rev Auditory Verbal Learning Test - 1 AM GOING TO READ A LIST OF WORDS.
LISTEN CAREFULLY, FOR WHEN I STOP YOU ARE TO REPEAT BACK AS
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MANY WORDS AS YOU CAN REMEMBER. IT DOESN'T MATTER WHAT
ORDER YOU REPEAT THEM. JUST TRY TO REMEMBER AS MANY AS YOU
CAN. Read List A 1 aloud, with a one second interval between each word. Use numbers
to keep track of the participant's pattern of recall. No feedback should be given. When
the participant indicates that he/she can recall no more words, the examiner rereads the
list after giving the following set o f instructions. NOW I'M GOING TO READ THE
SAME WORDS AGAIN, AND ONCE AGAIN WHEN I STOP I WANT YOU TO
TELL ME AS MANY WORDS AS YOU CAN REMEMBER, INCLUDING THE
WORDS YOU SAID THE FIRST TIME. IT DOESN'T MATTER IN WHAT ORDER
YOU SAY THEM. JUST SAY AS MANY WORDS AS YOU CAN REMEMBER,
WHETHER OR NOT YOU SAID THEM BEFORE. The Iixt is reread for Trials A3
through A5 using Trial A2 instructions each time. After trial A5, the examiner reads
List B with instructions as on the first A trial: NOW I'M GOING TO READ A
SECOND LIST OF WORDS. THIS TIME, YOU ARE TO SAY BACK AS MANY
WORDS OF THIS SECOND LIST AS YOU CAN REMEMBER. THE ORDER IN
WHICH YOU SAY THESE WORDS DOES NOT MATTER. JUST TRY TO
REMEMBER AS MANY AS YOU CAN. Immediately after recall B l, as for recall of
the first list (Trial A6) without further presentation o f those words: NOW TELL ME AS
MANY WORDS FROM THE FIRST LIST AS YOU CAN REMEMBER. After a
twentyminute delay period filed with other activity, as the patient to recall the words
from list A (TrialA7): NOW TELL ME AS MANY WORDS FROM THE FIRST LIST
AS YOU CAN REMEMBER.
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6. Trail Making Test (Part A) - Place the Part A sample sheet on the table directly in
front of the subject six inches from the edge of the table. Give subject the pencil and
say: ON THIS PAGE (point) ARE SOME NUMBERS. BEGIN AT THE NUMBER 1
(point to 1) AND DRAW A LINE FROM 1 TO 2 (point to 2), 2 TO 3 (point to 3), 3 TO
4 (point to 4), AND SO ON, IN ORDER UNTIL YOU REACH THE END (point to the
circle marked "end"). DRAW THE LINES AS FAST AS YOU CAN. READY! BEGIN!
If the subject completes the sample items correctly, and in manner which showa that
he/she knows what to do, say: GOOD! LETS TRY THE NEXT ONE. Give Part A of
the test following the instructions below.
If the subject makes a mistake on Sample A, point out the error and explain it.
The following explanations of mistakes serve as illustrations.
A. YOU STARTED WITH THE WRONG CIRCLE. THIS IS WHERE YOU
START (point to the number 1).
B. YOU SKIPPED THIS CIRCLE (point to the circle omitted). YOU SHOULD
GO FROM NUMBER 1 (point), TO 2 (point), 2 TO 3 (point), AND SO ON, UNTIL
YOU REACH THE CIRCLE MARKED END (point). If it is clear that the subject
intended to touch the circle but missed it, do not count it as an omission, but caution the
subject to touch the circles.
If the subject still cannot complete the sample, take his/her hand and guide the
pencil (eraser end down) through the trail. Then say: NOW YOU TRY IT. Return the
pencil to the subject and say: REMEMBER, BEGIN AT NUMBER 1 (point) AND
DRAW A LINE FROM 1 TO 2 (point to 2), 2 TO 3 (point to 3), 3 TO 4 (point to 4),
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AND SO ON IN ORDER, UNTIL YOU REACH TEH CIRCLE MARKED END
(point). DO NOT SKIP AROUND, BUT GO FROM ONE NUMBER TO THE NEXT
IN THE PROPER ORDER. REMEMBER TO WORK AS FAST AS YOU CAN.
READY! BEGIN! If the subject succeds this time, go on to Part A. If not, repeat the
procedure until he/she does or until it is evident that he/she cannot.
Test Instructions. ON THIS PAGE ARE NUMBERS FROM I TO 25. DO THIS
THE SAME WAY. BEGIN AT NUMBER 1 (point) AND DRAW A LINE FROM 1 TO
2 (point to 2), 2 TO 3 (point to 3), 3 TO 4 (point to 4) AND SO ON, IN ORDER,
UNTIL YOU REACH THE END (point to 25). REMEMBER, WORK AS FAST AS
YOU CAN. READY! BEGIN! Start timing and do not stop. Watch the subject closely
and correct any errors immediately by having the subject proceed from the point the
mistake occurred. Record the time to complete the test.

7. Trail Making Test (Part B) - NOW WE'LL TRY ANOTHER ONE. Place Sample B
in front o f the participant and say: ON THIS PAGE ARE SOME NUBERS AND
LETTERS. BEGIN AT NUMBER 1 (point) AND DRAW A LINE FROM 1 TO A
(point to A), A TO 2 (point to 2), 2 TO B (point to B), B TO 3 (point to 3), 3 TO C
(point to C), AND SO ON, IN ORDER UNTIL YOU REACH THE END (point to the
circle marked "end"). REMEMBER, FIRST YOU HAVE A NUMBER (point to 1),
THEN A LETTER (point to A), THEN A NUMBER (point to 2), THEN A LETTER
(point to B), AND SO ON. DRAW THE LINES AS FAST AS YOU CAN. READY!
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BEGIN! If the subject completes the sample correctly, say: GOOD. LETS TRY THE
NEXT ONE. Administer the test with the instructions below.
If the subject makes a mistake, point it out and explain it similarly to the
explanations for mistakes for part A. If the subject still cannot complete the sample,
guide his/her hand as before. Then repeat the instructions and encourage the subject to
try again. If the subject succeeds, procede to the test, if not, continue to explain it until
he/she does succeed, or until it becomes obvious that he/she cannot.
Test Instructions ON THIS PAGE ARE NUMBERS AND LETTERS. DO THIS
THE SAME WAY. BEGIN AT NUMBER 1 (point), AND DRAW A LINE FROM 1
TO A (point to A), A TO 2 (point to 2), 2 TO B (point to B), B TO 3 (point to 3), 3 TO
C (point to C), AND SO ON, IN ORDER, UNTIL YOU REACH THE END (point to
the circle marked "end"). REMEMBER, FIRST YOU HAVE A NUMBER (point to 1),
THEN A LETTER (point to A), THEN A NUMBER (point to 2), THEN A LETTER
(point to B), AND SO ON. DON NOT SKIP AROUND, BUT GO FROM ONE
CIRCLE TO THE NEXT IN PROPER ORDER. DRAW THE LINES AS FAST AS
YOU CAN. READY! BEGIN! Start timing and do not stop. If the subject makes an
error, call it to the subject's attention immediately and have him/her proceed from the
point the mistake occurred. Record the time to complete the test.

8. Block Design - Place four blocks in view of the subject and say: YOU SEE THESE
BLOCKS? THEY ARE ALL ALIKE. ON SOME SIDES THEY ARE ALL RED; ON
SOME, ALL WHITE; AND ON SOME, HALF RED AND HALF WHITE. Hold up one
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block and turn it to show each side. Then say: I'M GOING TO PUT THEM
TOGETHER TO MAKE A DESIGN, WATCH ME. Arrange the four blocks slowly into
the design shown on card 1, without exposing the card to the subject. Then, leaving the
model intact, give four other blocks to the subject and say: NOW MAKE ONE JUST
LIKE THIS. Start timing. Allow 60 seconds. If the subject successfully completes the
design within the time limit, proceed to Design 2. If the subject fails, say: WATCH ME
AGAIN. Demonstrate again using the subject’s blocks. Then scramble the dubject’s
blocks and say: NOW YOU TRY IT AGAIN AND BE SURE TO MAKE IT JUST
LIKE MINE. Start timing again and allow 60 seconds. Regardless of performance,
proceed to design 2. If the subject attempts to match the examiner’s design exactly (all
sides) tell him/her that only the top needs to be duplicated.
Design 2 Scramble the subject’s blocks. Remove the blocks that served as the model for
design 1 and put in their place the card marked (2). Say: THIS TIME WE ARE GOING
TO PUT THE BLOCKS TOGETHER TO MAKE THEM LOOK LIKE THIS
PICTURE. Point to the card, then say: WATCH ME FIRST. Construct the design
slowly, then say: YOU SEE THE TOPS OF THESE BLOCKS LOOK THE SAME AS
THIS PICTURE. Scramble the blocks used in the demonstration and say: NOW LOOK
AT THE PICTURE AND MAKE ONE JUST LIKE IT WITH THESE BLOCKS. GO
AHEAD. Allow 60 seconds. If the subject successfully completes the design, proceed to
Design 3. If the subject fails, scramble the blocks and say: WATCH ME AGAIN. Make
the design again, then scramble it and say: NOW TRY IT AGAIN. Allow 60 seconds.
Regardless of performance, continue to Design 3.
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Design 3-9 Scramble the blocks and put out the card marked (3). Say: NOW MAKE
ONE LIKE THIS. TRY TO WORK AS QUICKLY AS YOU CAN. TELL ME WHEN
YOU HAVE FINISHED. Start timing and allow 60 seconds. When the subject has
completed the design or time is up, scramble the block and continue with the next
design using the same instructions, or a shortened version once the subject understands
the task. For Design 6 say: NOW MAKE ONE LIKE THIS USING NINE BLOCKS. BE
SURE TO TELL ME WHEN YOU HAVE FINISHED. For Design 9, do not permit the
subject to rotate the card. Continue the test until the subject has failed 3 consecutive
trials. A two-trial design is considered failed only if both trials are failed.

9. Grooved Pegboard Test - THIS IS A PEGBOARD, AND THESE ARE PEGS. Point
to each, then pick up one of the pegs. ALL OF THE PEGS ARE THE SAME. THEY
HAVE A GROOVE. THAT IS, A ROUND SIDE, AND A SQUARE SIDE, AND SO
DO THE HOLES IN THE BOARD. WHAT YOU MUST DO IS MATCH THE
GROOVE OF THE PEG WITH THE GROOVE OF THE BOARD AND PUT THSES
PEGS INTO THE HOLES LIKE THIS. Demonstrate by filling the top row, then take
them out again. WHEN I SAY GO, BEGIN HERE AND PUT THE PEGS INTO THE
BOARD AS FAST AS YOU CAN USING ONLY YOUR (DOMINANT) HAND. FILL
THE TOP ROW COMPLETELY FROM THIS SIDE TO THIS SIDE (demonstrate left
to right when using right hand, and right to left when using left hand). DO NOT SKIP
ANY. FILL EACH ROW THE SAME WAY YOU FILLED THE TOP ROW. ANY
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QUESTIONS? READY, AS FAST AS YOU CAN GO. Begin timing and stop when
last peg is in its hole.

10. Digit Span Forward - I’M GOING TO SAY SOME NUMBERS. LISTEN
CAREFULLY, AND WHEN I AM THROUGH SAY THEM RIGHT AFTER ME. The
digits should be given at the rate of one per second. Let the pitch of voice drop on the
last digit of each trial. Administer both trials of each item, even if the subject passes
trial 1. Discontinue after failure on both trials of any item. Give 2 points if the subject
passes both trials, 1 point if the subject passes only 1, and 0 points if the subject fails
both trials.

11. Remember to give the RAVLT delay.

12. F-A-S Test - Ignore the instructions at the top of the page. I WANT YOU TO
NAME AS MANY WORDS AS YOU CAN THAT BEGIN WITHT THE LETTER OF
THE ALPHABET THAT I WILL GIVE YOU. THERE ARE TWO RULES. FIRST,
YOU CANNOT USE DIFFERENT FORMS OF THE SAME WORD. FOR EXAMPLE,
IF I GAVE YOU (G), YOU COULD SAY GO, BUT YOU COULD NOT THEN SAY
GOES OR GONE. SECOND, YOU CANNOT USE PROPER NAMES, FOR
EXAMPLE THE NAME OF A PERSON ORE A CITY. NOW HOW MANY WORDS
CAN YOU THINK OF THAT BEGIN WITHT THE LETTER

.Allow 60
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seconds, and write down all of the words that the subject says in the proper column
depending on the time that he/she says the word. Do not adminster animals.

13. Paced Auditory Serial Addition Test - 1 AM GOING TO ASK TO ADD
TOGETHER PAIRS OF SINGLE-DIGIT NUMBERS. YOU WILL HEAR A TAPERECORDED LIST OF NUMBERS READ ONE AFTER ANOTHER. I WILL ASK
YOU TO ADD THE NUMBERS IN PAIRS AND GIVE YOU ANSWERS OUT
LOUD. ALTHOUGH THIS IS REALLY A CONCENTRATION TASK, AND NOT A
TEST TO SEE HOW WELL YOU CAN ADD, IT MIGHT TO DO A LITLLE ADDING
BEFORE I EXPLAIN THE TASK IN MORE DETAIL. PLEASE ADD THE
FOLLOWING PAIRS OF NUMBERS TOGETHER AS FAST AS YOU CAN, AND
GIVE YOUR ANSWERS OUT LOUD: 3,8 (11); 4,9 (13); 7,8(15); 8,6(14); 8,9(17);
5,7( 12); 6,5( 11); 6,9( 15); 4,7(11); 7,6( 13). GOOD. If subject cannot add these numbers,
do not administer the test. THE TASK THAT I WANT YOU TO DO INVOLVES
ADDING TOGETHER PAIRS OF NUMBERS JUST AS YOU HAVE DONE,
EXCEPT THE NUMBERS WILL BE READ AS A LIST ONE AFTER THE OTHER.
LET ME GIVE YOU AN EXAMPLE WITH A SHORT, EASY LIST. SUPPOSE I
GAVE YOU THE FOLLOWING: 1,2,3,4. HERE’S WHAT YOU WOULD DO. AFTER
HEARING THE FIRST TWO NUMBERS ON THE LIST WHICH WERE 1,2, YOU
WOULD ADD THESE TOGETHER AND GIVE YOUR ANSWER, 3, 1 + 2 =3. THE
NEXT NUMBER ON THE LIST IS 3, SO WHEN YOU HEARD IT, YOU WOULD
ADD THIS NUMBER TO THE NUMBER RIGHT BEFORE IT ON THE LIST
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WHICH WAS 2, AND YOU WOULD GIVE YOUR ANSWER 5,2 + 3 = 5. ARE YOU
FOLLOWING SO FAR? THE LAST NUMBER YOU HEARD WAS 4 (REMEMBER
THE LIST WAS 1,2,3,4), SO YOU WOULD ADD 4 TO THE NUMBER RIGHT
BEFORE IT WHICH WAS 3, AND GIVE YOUR ANSWER 7, 3 + 4 = 7. THE
IMPORTANT THING TO REMEMBER IS THAT YOU MUST ADD EACH
NUMBER ON THE LIST TO THE NUMBER BEFORE IT ON THE LIST, AND NOT
TO THE ANSWER YOU HAVE JUST GIVEN. YOU CAN FORGET YOUR
ANSWERS AS SOON AS YOU HAVE SAID THEM. ALL YOU HAVE TO
REMEMBER IS THE LAST DIGIT THAT YOU HEARD AND ADD IT TO THE
NEXT DIGIT THAT YOU HEAR. O.K.? LET’S TRY A SHORT LIST AGAIN, ONLY
THIS TIME YOU SAY THE ANSWERS. READY? 1,2 (3); 3 (5); 4 (7); NOW LET’S
TRY ANOTHER, LONGER PRACTICE LIST OF NUMBERS, THIS TIME THE
NUMBERS ON THE LIST WILL NOT BE IN ANY PARTICULAR ORDER.
READY? 4,6 (10); 1 (7); 8 (9); 8 (16); 4 (12); 3 (7); 8 (11); 2 (10); 7 (9). GOOD.
If the subject has difficult understanding the oral directions, then provide a
written demonstration. THAT SOUNDS COMPLICATED, LET ME SHOW YOU
WHAT I MEAN. Write down a list of numbers (5,3,7,4,2) YOU SEE, YOU ADD THE
5 AND THE 3 TOGETHER AND SAY 8. THEN YOU HAVE TO FORGET THE 8
AND REMEMBER THE 3. WHEN THE 7 COMES ALONG, YOU ADD IT TO THE
3, AND SAY 10. NOW YOU HAVE TO REMEMBER THE 7. ALRIGHT. WHAT DO
YOU SAY AFTER 4? Continue until the subject understands what to do. Say:
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IT’S VERY EASY WHEN ALL THE NUMBERS ARE WRITTEN DOWN FOR YOU.
TRY IT WITH ME SAYING SOME NUMBERS TO YOU. Say some more.
REMEMBER, I SAID THE NUMBERS WOULD BE TAPE-RECORDED?
THE TASK IS NOT EASY, AND NO ONE IS EXPECTED TO GET ALL OF THE
ANSWERS RIGHT. THE HARD PART IS KEEPING UP WITH THE SPEED OF THE
RECORDING. HOWEVER, IF YOU CAN’T ANSWER IN TIME, DON’T WORRY.
JUST WAIT UNTIL YOU HEAR TWO MORE NUMBERS; ADD THEM
TOGETHER, AND GO ON FROM THERE. O.K.? I’LL PLAY A PRACTICE LIST OF
NUMBERS, AND GET YOU TO GIVE ME THE ANSWERS. Play practice list.
YOU SEE WHAT I MEAN ABOUT THE TASK MEASURING HOW WELL
YOU CAN CONCENTRATE. IT DOESN’T HAVE ANYTHING TO DO WITH HOW
SMART YOU ARE. NOW WE’LL TRY THE FIRST REAL TRIAL. THIS TRIAL IS
JUST THE SAME AS THE PRACTICE TRIAL YOU’VE JUST DONE, EXCEPT
THAT IT IS SIX TIMES AS LONG, SO IT GOES ON FOR ABOUT THREE
MINUTES. DON’T WORRY IF YOU MAKE ADDING MISTAKES, OR MISS SOME
ANSWERS. THIS IS A DIFFICULT TASK. I WANT TO SEE NOT ONLY HOW
LONG YOU CAN KEEP GOING WITHOUT STOPPING, BUT ALSO HOW
QUICKLY YOU CAN PICK UP AGAIN IF YOU DO STOP. NO ONE IS EXPECTED
TO GET ALL THE ANSWERS. AFTER THIS TRIAL WE WILL TAKE A BREAK
AND THEN DO ANOTHER TRIAL AT A FASTER SPEED. Follow along with
subject writing the subject’s responses in the blanks provided.
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